{"content":"<li class=\"n-box-item date-title\" data-end=\"1551761999\" data-start=\"1551675600\" data-txt=\"Monday, December 23, 2019\">Monday, March  4, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3439689\" data-ts=\"1551742565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFH\" target=\"_blank\">AFH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439689-atlas-financialminus-47-ceo-stresses-increase-to-reserve-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Atlas Financial -47% as CEO stresses increase to reserve estimates</a></h4><ul>   <li>Atlas Financial Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AFH' title='Atlas Financial Holdings'>AFH</a>) has crashed aftermarket, <font color=\"red\">down 46.6%</font>, after an earnings report that noted the need to boost its reserve estimates for unpaid losses.</li>    <li>That's mainly due to bodily injury claims from accident years 2016 and prior, CEO Scott Wollney says. \"These claims are showing higher severity and have been open for longer periods than we had estimated.</li>    <li>\"Specifically, we strengthened reserves to account for the possibility of higher costs for the tail on these prior accident years.\"</li>    <li>The company's still addressing \"historic challenges affecting commercial automobile insurance generally and in our book of business specifically,\" Wollney says, but thinks that more recent claim closure data back ups the company's efficacy.</li>    <li>Shares had <font color=\"red\">fallen 24.5%</font> during the regular session ahead of the earnings release.</li>    <li>Revenues fell nearly 12% Y/Y and missed expectations.</li>    <li><a href=\"https://seekingalpha.com/article/4246260-atlas-financial-holdings-2018-q4-results-earnings-call-slides\" target=\"_blank\">Earnings call slides</a></li>    <li><a href=\"https://seekingalpha.com/pr/17432486-atlas-financial-holdings-announces-unaudited-fourth-quarter-2018-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3439689\" data-linked=\"Atlas Financial -47% as CEO stresses increase to reserve estimates\" data-tweet=\"$AFH - Atlas Financial -47% as CEO stresses increase to reserve estimates https://seekingalpha.com/news/3439689-atlas-financialminus-47-ceo-stresses-increase-to-reserve-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3439689-atlas-financialminus-47-ceo-stresses-increase-to-reserve-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439684\" data-ts=\"1551740174\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HUYA\" target=\"_blank\">HUYA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439684-huyaplus-7_4-after-metrics-jump-revenues-double\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Huya +7.4% after metrics jump, revenues more than double</a></h4><ul>   <li>Huya Broadcasting (NYSE:<a href='https://seekingalpha.com/symbol/HUYA' title='Huya Broadcasting'>HUYA</a>) is <font color=\"green\">up 7.4%</font> after hours after it topped high estimates with its Q4 revenues, which more than doubled year-over year.</li>    <li>Net income jumped even more, up 1,900% as reported to 166.9M yuan (about $14.5M). Non-GAAP net income rose 487% to 166.9M yuan (about $24.3M).</li>    <li>In metrics, average mobile monthly active users hit 50.7M (up 30.7%); average MAUs overall rose 34.5% to 116.6M.</li>    <li>Total number of paying users jumped 73% to 4.8M.</li>    <li>Revenue breakout: Live streaming, 1.44B yuan (up 108%); Advertising and others, 63.15M yuan (up 30.7%).</li>    <li>For Q1, it's guiding to revenues of 1.51B-1.55B yuan (growth of 79%-83.7%).</li>    <li><a href=\"http://ir.huya.com/\" target=\"_blank\">Conference call</a> to come at 8 p.m ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439679-huya-broadcasting-beats-0_06-beats-revenue\" target=\"_blank\">Huya Broadcasting beats by $0.06, beats on revenue</a> (Mar. 04 2019)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439682-yy-gains-revenues-grow-28-percent-q4\" target=\"_blank\">YY gains after revenues grow 28% in Q4</a> (Mar. 04 2019)</li>    <li><a href=\"https://seekingalpha.com/pr/17432661-huya-inc-reports-fourth-quarter-fiscal-year-2018-unaudited-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3439684\" data-linked=\"Huya +7.4% after metrics jump, revenues more than double\" data-tweet=\"$HUYA - Huya +7.4% after metrics jump, revenues more than double https://seekingalpha.com/news/3439684-huyaplus-7_4-after-metrics-jump-revenues-double?source=tweet\" data-url=\"https://seekingalpha.com/news/3439684-huyaplus-7_4-after-metrics-jump-revenues-double\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439680\" data-ts=\"1551738874\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439680-gme-nvta-ps-and-soi-among-after-hours-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GME, NVTA, PS and SOI among after hours movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/OTIC' title='Otonomy'>OTIC</a> <font color=\"green\">+5.5%</font>. <a href='https://seekingalpha.com/symbol/DERM' title='Dermira'>DERM</a> <font color=\"green\">+4.9%</font>. <a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a> <font color=\"green\">+3.9%</font>. <a href='https://seekingalpha.com/symbol/SOI' title='Solaris Oilfield Infrastructure'>SOI</a> <font color=\"green\">+3.2%</font>. <a href='https://seekingalpha.com/symbol/CTBB' title='Qwest Corporation 6.5% Notes'>CTBB</a> <font color=\"green\">+3.1%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/USAT' title='USA Technologies, Inc.'>USAT</a> <font color=\"red\">-7.8%</font>. <a href='https://seekingalpha.com/symbol/PS' title='Pluralsight, Inc.'>PS</a> <font color=\"red\">-7.6%</font>. <a href='https://seekingalpha.com/symbol/NVTA' title='Invitae'>NVTA</a> <font color=\"red\">-5.8%</font>. <a href='https://seekingalpha.com/symbol/GAIA' title='Gaia Inc.'>GAIA</a> <font color=\"red\">-3.7%</font>. <a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a> <font color=\"red\">-3.2%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439680\" data-linked=\"GME, NVTA, PS and SOI among after hours movers\" data-tweet=\"$OTIC $DERM $GME - GME, NVTA, PS and SOI among after hours movers https://seekingalpha.com/news/3439680-gme-nvta-ps-and-soi-among-after-hours-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3439680-gme-nvta-ps-and-soi-among-after-hours-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439677\" data-ts=\"1551738034\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPTA\" target=\"_blank\">CPTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439677-capitala-financeminus-1_3-nii-nav-declines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capitala Finance -1.3% as NII, NAV declines</a></h4><ul><li>Capitala Finance (NASDAQ:<a href='https://seekingalpha.com/symbol/CPTA' title='Capitala Finance Corp'>CPTA</a>) <font color=\"red\">slips 1.3%</font> in after-hours trading after <a href=\"https://seekingalpha.com/pr/17432556-capitala-finance-corp-reports-fourth-quarter-full-year-2018-results\" target=\"_blank\">Q4 net investment income </a>of $3.5M, or 22 cents per share, misses the average analyst estimate of  35 cents.</li><li>Compares with $4.2M, or 26 cents per share, in Q4 2017.</li><li>Net asset value per share of $11.88 at Dec. 31, 2018, declines from $12.71 at Sept. 30, 2018.</li><li>Originated $48.9M of new investments in Q4 and received $27.3M of repayments.</li><li>Q4 total investment income of $11.3M fell from $11.6M in the year-ago quarter due to lower PIK income.</li><li><a href=\"https://www.globenewswire.com/Tracker?data=ibh3fMDB4RvB0Xwn05t4jxHqOfuw8NcZh5vSx86MkvhMyTjixitP7f3HMV2PC9T1WsancBzkANddLyHC2JP2tvM5_CKChUYah5WB0wznqIJksbE8VKkNUrccMU7A4qU4\" target=\"_blank\">Conference call</a> on March 5 at 8:30 AM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439646-capitala-finance-misses-0_13-misses-revenue\" target=\"_blank\">Capitala Finance misses by $0.13, misses on revenue</a> (March 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439677\" data-linked=\"Capitala Finance -1.3% as NII, NAV declines\" data-tweet=\"$CPTA - Capitala Finance -1.3% as NII, NAV declines https://seekingalpha.com/news/3439677-capitala-financeminus-1_3-nii-nav-declines?source=tweet\" data-url=\"https://seekingalpha.com/news/3439677-capitala-financeminus-1_3-nii-nav-declines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439664\" data-ts=\"1551736720\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PS\" target=\"_blank\">PS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439664-pluralsight-announces-senior-note-follow-on-offerings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pluralsight announces senior note, follow-on offerings</a></h4><ul><li>Pluralsight (NASDAQ:<a href='https://seekingalpha.com/symbol/PS' title='Pluralsight, Inc.'>PS</a>) <a href=\"https://seekingalpha.com/pr/17432585-pluralsight-inc-announces-450-million-convertible-notes-offering\" target=\"_blank\">announces</a> a $450M convertible note offering of senior notes due 2024 in a private placement.</li><li>Initial purchasers will have a 13-day option to buy up to an additional $67.5M of notes.</li><li>Pluralsight also <a href=\"https://seekingalpha.com/pr/17432576-pluralsight-inc-announces-proposed-follow-offering-selling-stockholders\" target=\"_blank\">announces</a> a proposed follow-on offering by selling shareholders with about 13.6M shares involved. Underwriters will have a 30-day option to purchase an additional 2M shares. Pluralsight won't receive proceeds from the sale.</li><li>Pluralsight shares are <font color=\"red\">down 1.5%</font> to $32.50.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439664\" data-linked=\"Pluralsight announces senior note, follow-on offerings\" data-tweet=\"$PS - Pluralsight announces senior note, follow-on offerings https://seekingalpha.com/news/3439664-pluralsight-announces-senior-note-follow-on-offerings?source=tweet\" data-url=\"https://seekingalpha.com/news/3439664-pluralsight-announces-senior-note-follow-on-offerings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439660\" data-ts=\"1551736314\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EAF\" target=\"_blank\">EAF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439660-graftech-backer-files-to-sell-shares-stock-slips-1_6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Graftech backer files to sell shares; stock slips 1.6%</a></h4><ul><li>Brookfield Business <a href=\"https://seekingalpha.com/filing/4386572\" target=\"_blank\">files registration</a> for the sale of 17.5M shares of its Graftech (NYSE:<a href='https://seekingalpha.com/symbol/EAF' title='GrafTech International'>EAF</a>) stake.</li><li>Shares are <font color=\"red\">down 1.6%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439660\" data-linked=\"Graftech backer files to sell shares; stock slips 1.6%\" data-tweet=\"$EAF - Graftech backer files to sell shares; stock slips 1.6% https://seekingalpha.com/news/3439660-graftech-backer-files-to-sell-shares-stock-slips-1_6?source=tweet\" data-url=\"https://seekingalpha.com/news/3439660-graftech-backer-files-to-sell-shares-stock-slips-1_6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439658\" data-ts=\"1551736164\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCX\" target=\"_blank\">OCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439658-oncocyte-up-1-after-hours-on-start-of-validation-of-lung-cancer-liquid-biopsy-test\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OncoCyte up 1% after hours on start of validation of lung cancer liquid biopsy test</a></h4><ul><li>OncoCyte (NYSEMKT:<a href='https://seekingalpha.com/symbol/OCX' title='OncoCyte Corporation'>OCX</a>) has <a href=\"https://seekingalpha.com/pr/17432482-oncocyte-announces-initiation-analytical-validation-study\" target=\"_blank\">initiated </a>a validation study of DermaVu Lung, its liquid biopsy test for lung cancer. Assuming all goes well, the test will be commercially available in H2.</li><li>Shares are up <font color=\"green\">1%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439658\" data-linked=\"OncoCyte up 1% after hours on start of validation of lung cancer liquid biopsy test\" data-tweet=\"$OCX - OncoCyte up 1% after hours on start of validation of lung cancer liquid biopsy test https://seekingalpha.com/news/3439658-oncocyte-up-1-after-hours-on-start-of-validation-of-lung-cancer-liquid-biopsy-test?source=tweet\" data-url=\"https://seekingalpha.com/news/3439658-oncocyte-up-1-after-hours-on-start-of-validation-of-lung-cancer-liquid-biopsy-test\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439643\" data-ts=\"1551735115\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HZNP\" target=\"_blank\">HZNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439643-horizon-pharma-commences-300m-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Horizon Pharma commences $300M equity offering</a></h4><ul><li>Horizon Pharma plc (NASDAQ:<a href='https://seekingalpha.com/symbol/HZNP' title='Horizon Pharma plc'>HZNP</a>) <a href=\"https://seekingalpha.com/pr/17432496-horizon-pharma-plc-announces-proposed-public-offering-ordinary-shares\" target=\"_blank\">launches </a>a $300M public offering of ordinary shares. Underwriters over-allotment is an additional $45M of stock. Price, volume and terms have yet to be announced.</li><li>Net proceeds will help fund the retirement of outstanding debt.</li><li>Shares are up a fraction after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439643\" data-linked=\"Horizon Pharma commences $300M equity offering\" data-tweet=\"$HZNP - Horizon Pharma commences $300M equity offering https://seekingalpha.com/news/3439643-horizon-pharma-commences-300m-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3439643-horizon-pharma-commences-300m-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439639\" data-ts=\"1551734930\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTZ\" target=\"_blank\">HTZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439639-hertz-globalminus-2-after-block-trades-prices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hertz Global -2% after block trades prices</a></h4><ul><li>Hertz Global (NYSE:<a href='https://seekingalpha.com/symbol/HTZ' title='Hertz Global Holdings, Inc.'>HTZ</a>) is <font color=\"red\">down 2.25%</font> in AH trading to $19.60 after a 5M share block being offered is reported by Bloomberg to be priced in a range of $19.60 to $19.65.</li><li>Shares of Hertz are up 45% YTD in a move that has sent some shorts scrambling.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439639\" data-linked=\"Hertz Global -2% after block trades prices\" data-tweet=\"$HTZ - Hertz Global -2% after block trades prices https://seekingalpha.com/news/3439639-hertz-globalminus-2-after-block-trades-prices?source=tweet\" data-url=\"https://seekingalpha.com/news/3439639-hertz-globalminus-2-after-block-trades-prices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439632\" data-ts=\"1551734473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRM\" target=\"_blank\">CRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439632-salesforceminus-2_6-on-downside-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Salesforce -2.6% on downside outlook</a></h4><ul><li>Salesforce (NYSE:<a href='https://seekingalpha.com/symbol/CRM' title='Salesforce.com, Inc.'>CRM</a>) <font color=\"red\">drops 2.6%</font> after it reports Q4 beats with 26% Y/Y revenue growth and downside guidance. Q4 subscription and support revenue totaled $3.38B, up 26% Y/Y. Professional services and other revenue came in at $228M, up 16% Y/Y.</li><li>Downside Q1 guidance has revenue from $3.67B to $3.68B (consensus: $3.69B) and EPS from $0.60 to $0.61 (consensus: $0.63).</li><li>In-line FY20 guidance has revenue from $15.95B to $16.05B (consensus: $15.99B) and EPS from $2.74 to $2.76 (consensus: $2.76).</li><li>FY23 target has revenue of $26B to $28B.</li><li>Earnings call starts at 5 PM ET with a webcast <a href=\"https://investor.salesforce.com/about-us/investor/overview/default.aspx\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17432469-salesforce-announces-record-fourth-quarter-full-year-fiscal-2019-results\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439614-salesforce-com-beats-0_15-beats-revenue\" target=\"_blank\">Salesforce.com beats by $0.15, beats on revenue</a> (March 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439632\" data-linked=\"Salesforce -2.6% on downside outlook\" data-tweet=\"$CRM - Salesforce -2.6% on downside outlook https://seekingalpha.com/news/3439632-salesforceminus-2_6-on-downside-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3439632-salesforceminus-2_6-on-downside-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439631\" data-ts=\"1551734469\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVTA\" target=\"_blank\">NVTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439631-invitae-launches-125m-equity-offering-shares-down-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Invitae launches $125M equity offering; shares down 4% after hours</a></h4><ul><li>Invitae (NYSE:<a href='https://seekingalpha.com/symbol/NVTA' title='Invitae'>NVTA</a>) slips <font color=\"red\">4%</font> after hours in response to its $125M <a href=\"https://seekingalpha.com/pr/17432490-invitae-announces-proposed-public-offering-common-stock\" target=\"_blank\">public offering </a>of common stock. Underwriters over-allotment will be an additional $18.75M of stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439631\" data-linked=\"Invitae launches $125M equity offering; shares down 4% after hours\" data-tweet=\"$NVTA - Invitae launches $125M equity offering; shares down 4% after hours https://seekingalpha.com/news/3439631-invitae-launches-125m-equity-offering-shares-down-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3439631-invitae-launches-125m-equity-offering-shares-down-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439630\" data-ts=\"1551734364\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GME\" target=\"_blank\">GME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439630-gamestopplus-4-after-dialing-up-buybacks-retiring-debt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GameStop +4% after dialing up more buybacks, retiring debt</a></h4><ul><li>GameStop (NYSE:<a href='https://seekingalpha.com/symbol/GME' title='GameStop Corp.'>GME</a>) announces a new $300M share repurchase authorization to replace the previous share repurchase authorization which had $170M remaining.</li><li>The repurchase authorization does not require GameStop to acquire any specific number of shares and may be terminated at any time.</li><li>The company also retired $350M worth of debt and set a $0.38 per share quarterly dividend payout rate.</li><li>GME  <font color=\"green\">+4.15%</font> after hours to  $12.05.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17432488-gamestop-declares-quarterly-cash-dividend-announces-intent-retire-2019-notes-approves-new-300\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3439630\" data-linked=\"GameStop +4% after dialing up more buybacks, retiring debt\" data-tweet=\"$GME - GameStop +4% after dialing up more buybacks, retiring debt https://seekingalpha.com/news/3439630-gamestopplus-4-after-dialing-up-buybacks-retiring-debt?source=tweet\" data-url=\"https://seekingalpha.com/news/3439630-gamestopplus-4-after-dialing-up-buybacks-retiring-debt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>55&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439612\" data-ts=\"1551733483\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASND\" target=\"_blank\">ASND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439612-ascendis-pharma-launches-equity-offering-shares-down-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ascendis Pharma launches equity offering; shares down 1% after hours</a></h4><ul><li>Ascendis Pharma A/S (NASDAQ:<a href='https://seekingalpha.com/symbol/ASND' title='Ascendis Pharma'>ASND</a>) slips <font color=\"red\">1%</font> after hours in response to its <a href=\"https://seekingalpha.com/pr/17432431-ascendis-pharma-s-announces-proposed-public-offering-adss\" target=\"_blank\">$400M public offering</a> of American Depositary Shares (ADSs). Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439612\" data-linked=\"Ascendis Pharma launches equity offering; shares down 1% after hours\" data-tweet=\"$ASND - Ascendis Pharma launches equity offering; shares down 1% after hours https://seekingalpha.com/news/3439612-ascendis-pharma-launches-equity-offering-shares-down-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3439612-ascendis-pharma-launches-equity-offering-shares-down-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439605\" data-ts=\"1551733135\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XON\" target=\"_blank\">XON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439605-intrexon-continues-slide-down-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intrexon continues slide, down 18%</a></h4><ul><li>One-time biotech darling Intrexon (<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a> <font color=\"red\">-18.1%</font>) can't find a friend. Shares have sold off almost <font color=\"red\">50%</font> in two trading days after posting underwhelming Q4 results and facing a capital raise.</li><li>Today, it announced an <a href=\"https://seekingalpha.com/pr/17431281-intrexon-surterra-wellness-collaborate-botticelli-next-generation-plant-propagation-cannabis\" target=\"_blank\">out-licensing deal</a> with Suterra Wellness who will use its Botticelli plant propagation platform for its cannabis varieties for the Florida market. Intrexon will be eligible for royalties on plantlet usage.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439605\" data-linked=\"Intrexon continues slide, down 18%\" data-tweet=\"$XON - Intrexon continues slide, down 18% https://seekingalpha.com/news/3439605-intrexon-continues-slide-down-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3439605-intrexon-continues-slide-down-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439604\" data-ts=\"1551732921\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LEAF\" target=\"_blank\">LEAF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439604-leaf-groupminus-3_8-no-3-holder-presses-for-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Leaf Group -3.8% as No. 3 holder presses for sale</a></h4><ul>   <li>Ahead of earnings to come after the close today, Leaf Group (NYSE:<a href='https://seekingalpha.com/symbol/LEAF' title='Leaf Group Ltd.'>LEAF</a>) is <font color=\"red\">down 3.8%</font> after its No. 3 shareholder issued an open letter calling on the company to <a href=\"https://seekingalpha.com/filing/4385975\" target=\"_blank\">explore an immediate sale</a>.</li>    <li>In a filing noting a 7.8% stake, Osmium says: \"We strongly encourage the Leaf board of directors to explore separate sales of the assets comprising its two business segments, Media and Marketplaces, instead of continuing to operate the two businesses as a combined public company.\"</li>    <li>Operating as a combined company is a mistake, Osmium says, and \"The market has correctly identified these flaws and valued Leaf at a fraction of its private market value, which we believe would be unlocked by a strategic buyer through both cost and revenue synergies.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439604\" data-linked=\"Leaf Group -3.8% as No. 3 holder presses for sale\" data-tweet=\"$LEAF - Leaf Group -3.8% as No. 3 holder presses for sale https://seekingalpha.com/news/3439604-leaf-groupminus-3_8-no-3-holder-presses-for-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3439604-leaf-groupminus-3_8-no-3-holder-presses-for-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439603\" data-ts=\"1551732704\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCK\" target=\"_blank\">MCK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439603-potential-purdue-bankruptcy-weighs-on-drug-wholesalers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Potential Purdue bankruptcy weighs on drug wholesalers</a></h4><ul><li>Drug distributors McKesson (<a href='https://seekingalpha.com/symbol/MCK' title='McKesson Corporation'>MCK</a> <font color=\"red\">-3.6%</font>), AmerisourceBergen (<a href='https://seekingalpha.com/symbol/ABC' title='AmerisourceBergen Corporation'>ABC</a> <font color=\"red\">-3.3%</font>) and Cardinal Health (<a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health Inc.'>CAH</a> <font color=\"red\">-4.4%</font>) are in the red in apparent sympathy with many opioid drugmakers in the wake of a possible <a href=\"https://seekingalpha.com/news/3439562-painkiller-stocks-red-possible-purdue-bankruptcy\" target=\"_blank\">bankruptcy filing</a> by Purdue Pharma connected to its role in the opioid crisis. Purdue is facing about 2,000 lawsuit over its alleged misbehavior promoting OxyContin.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439603\" data-linked=\"Potential Purdue bankruptcy weighs on drug wholesalers\" data-tweet=\"$MCK $ABC $CAH - Potential Purdue bankruptcy weighs on drug wholesalers https://seekingalpha.com/news/3439603-potential-purdue-bankruptcy-weighs-on-drug-wholesalers?source=tweet\" data-url=\"https://seekingalpha.com/news/3439603-potential-purdue-bankruptcy-weighs-on-drug-wholesalers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439591\" data-ts=\"1551729967\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UPS\" target=\"_blank\">UPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439591-moodys-negative-on-ups\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Moody&#39;s negative on UPS</a></h4><ul> <li>UPS (<a href='https://seekingalpha.com/symbol/UPS' title='United Parcel Service, Inc.'>UPS</a> <font color=\"red\">-1.7%</font>) trades at a session low after Moody's changes its ratings <a href=\"https://www.moodys.com/research/Moodys-changes-UPS-rating-outlook-to-negative-affirms-A1-senior--PR_395889\" target=\"_blank\">outlook</a> to Negative from Stable. Key snippets from the rating agency's report are posted below.</li> <li>\"The negative outlook reflects the potential for funded debt to remain elevated through and beyond 2020 because of 1) sustained significant returns to shareholders during a period of weaker free cash flow generation because of stepped up capital investment and 2) ongoing contributions to the company's defined-benefit pension plans.\"</li> <li>\"Actual operating results and debt levels have trailed Moody's expectations at this point, and funding either increased share buybacks or pension contributions may weaken the credit profile.\"</li> <li>\"Moody's also anticipates that UPS' current transformation strategy meant to improve its operating margin and cash flow generation will modestly improve operating margins going forward. While it is unlikely for UPS to attain the operating margins of the past, Moody's does anticipate that UPS will remain the industry's operating margin leader. Moody's projects operating margin at about 10% for 2019, lower than historical levels and also lower because of the change in 2018 to how companies report pension expense in their GAAP income statements.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439591\" data-linked=\"Moody&#39;s negative on UPS\" data-tweet=\"$UPS - Moody&#39;s negative on UPS https://seekingalpha.com/news/3439591-moodys-negative-on-ups?source=tweet\" data-url=\"https://seekingalpha.com/news/3439591-moodys-negative-on-ups\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439589\" data-ts=\"1551729516\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACIA\" target=\"_blank\">ACIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439589-acacia-communicationsplus-3-craig-hallum-gives-high-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acacia Communications +3% as Craig-Hallum gives high target</a></h4><ul>   <li>Acacia Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications'>ACIA</a>) is <font color=\"green\">up 3%</font> after a Craig-Hallum launch at Buy with a Street-high price target.</li>    <li>The firm set its target at $68, implying 22% upside from today's higher price.</li>    <li>It's not a cheap stock, analyst Richard Shannon writes, but \"a product cycle potentially more powerful than 2016\u2019s has just begun.\" The company's already starting to see sustained growth this year and it's poised for 25-30% growth over at least the next two years, with the help of a sustainable advantage in coherent DSP. (h/t Bloomberg)</li>    <li>Shares are <font color=\"green\">up 42.6%</font> so far in 2019.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3439589\" data-linked=\"Acacia Communications +3% as Craig-Hallum gives high target\" data-tweet=\"$ACIA - Acacia Communications +3% as Craig-Hallum gives high target https://seekingalpha.com/news/3439589-acacia-communicationsplus-3-craig-hallum-gives-high-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3439589-acacia-communicationsplus-3-craig-hallum-gives-high-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439588\" data-ts=\"1551729370\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439588-splunk-drops-alphabet-launches-cybersecurity-product\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Splunk drops as Alphabet launches cybersecurity product</a></h4><ul><li>Alphabet's (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color='green'>+0.2%</font>)(<a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a> <font color='green'>+0.2%</font>) Chronicle <a href=\"https://www.cnbc.com/2019/03/04/alphabet-launches-backstory-from-chronicle.html\" target=\"_blank\">launches</a> its first commercial product, a security data and threat intelligence platform called Backstory. Chronicle is the cybersecurity division spun out from Alphabet's X moonshot lab.</li><li>Backstory uses Google's infrastructure and analytic capabilities to help analysts parse potential threats from a lot of quickly incoming information.</li><li>Carbon Black (<a href='https://seekingalpha.com/symbol/CBLK' title='Carbon Black'>CBLK</a> <font color='red'>-1.1%</font>) was part of Backstory's beta and has joined the product's offerings with its endpoint security data.</li><li>Chronicle didn't provide pricing, but it will be based on the size of the client's company rather than the volume of data.</li><li>Competitors: Other security information and event management providers include IBM (<a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a> <font color='red'>-0.8%</font>), Rapid7 (<a href='https://seekingalpha.com/symbol/RPD' title='Rapid7'>RPD</a> <font color='red'>-2.9%</font>), and Splunk (<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a> <font color='red'>-5.2%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3439588\" data-linked=\"Splunk drops as Alphabet launches cybersecurity product\" data-tweet=\"$GOOG $GOOGL $CBLK - Splunk drops as Alphabet launches cybersecurity product https://seekingalpha.com/news/3439588-splunk-drops-alphabet-launches-cybersecurity-product?source=tweet\" data-url=\"https://seekingalpha.com/news/3439588-splunk-drops-alphabet-launches-cybersecurity-product\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439586\" data-ts=\"1551728270\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439586-unitiminus-5_3-pursues-credit-amendment-affecting-dividend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uniti -5.3% as it pursues credit amendment, affecting dividend</a></h4><ul>   <li>Uniti Group (NASDAQ:<a href='https://seekingalpha.com/symbol/UNIT' title='Uniti Group Inc.'>UNIT</a>) is slipping, <font color=\"red\">down 5.3%</font>, after an <a href=\"https://seekingalpha.com/filing/4385724\" target=\"_blank\">SEC filing</a> says it's started a process to amend its credit, including a waiver of any default coming from a going-concern modification to an audit opinion upcoming from PricewaterhouseCoopers.</li>    <li>The company says it may agree to some restrictions under the credit agreement during the pending bankruptcy of its biggest customer, Windstream Holdings (<a href=\"http://seekingalpha.com/symbol/WIN\" target=\"_blank\">WIN</a> <font color=\"red\">-5.6%</font>) -- including a provision that would limit future dividends to 90% of taxable income excluding capital gains.</li>      <li>The company now expects dividends attributable to capital stock for 2019 tax year to be limited to about $250M, and aggregate dividends for the upcoming four quarters to be limited to about $140M. For the 2018 year, it paid attributable dividends of about $435M and in January it paid an attributable dividend of about $110M related to the 2019 tax year.</li><li>Uniti delayed its planned earnings release last week as it reviewed the impact of Windstream's bankruptcy; it expects to provide its results and a business update no later than March 18.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439586\" data-linked=\"Uniti -5.3% as it pursues credit amendment, affecting dividend\" data-tweet=\"$UNIT $WINMQ - Uniti -5.3% as it pursues credit amendment, affecting dividend https://seekingalpha.com/news/3439586-unitiminus-5_3-pursues-credit-amendment-affecting-dividend?source=tweet\" data-url=\"https://seekingalpha.com/news/3439586-unitiminus-5_3-pursues-credit-amendment-affecting-dividend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>236&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439562\" data-ts=\"1551727093\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENDP\" target=\"_blank\">ENDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439562-painkiller-stocks-in-red-on-possible-purdue-bankruptcy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Painkiller stocks in the red on possible Purdue bankruptcy</a></h4><ul><li>The broad market's down day notwithstanding, opioid drugmakers are under modest pressure in apparent response to a <a href=\"https://www.reuters.com/article/us-purduepharma-bankruptcy-exclusive/exclusive-oxycontin-maker-purdue-pharma-exploring-bankruptcy-sources-idUSKCN1QL1KL\" target=\"_blank\">report </a>that privately held Purdue Pharma is mulling a Chapter 11 bankruptcy filing to protect itself from the ~2,000 lawsuits against it related to its marketing practices for OxyContin (oxycodone HCl), the \"poster child\" painkiller in the U.S. opioid crisis.</li><li>More than 1,600 of the cases are consolidated in an Ohio federal court.</li><li>In 2007, the company and three executives pleaded guilty in to federal charges of misbranding OxyContin and agreed to pay $634.5M in penalties.</li><li>Selected tickers: Endo International (<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a> <font color=\"red\">-14.9%</font>); INSYS Therapeutics (<a href='https://seekingalpha.com/symbol/INSY' title='Insys Therapeutics, Inc.'>INSY</a> <font color=\"red\">-3.8%</font>); Titan Pharmaceuticals (<a href='https://seekingalpha.com/symbol/TTNP' title='Titan Pharmaceuticals, Inc.'>TTNP</a> <font color=\"red\">-5.4%</font>); Dr. Reddy's Laboratories (<a href='https://seekingalpha.com/symbol/RDY' title='Dr. Reddy&#39;s Laboratories Limited'>RDY</a> <font color=\"red\">-0.6%</font>), Mallinckrodt (<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a> <font color=\"red\">-6.5%</font>), Perrigo (<a href='https://seekingalpha.com/symbol/PRGO' title='Perrigo Company'>PRGO</a> <font color=\"red\">-1%</font>), AbbVie (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color=\"red\">-1%</font>), Opiant Pharmaceuticals (<a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color=\"red\">-0.6%</font>), Allergan (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color=\"red\">-1.6%</font>), Teva Pharmaceutical Industries (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color=\"red\">-1.8%</font>), Alkermes plc (<a href='https://seekingalpha.com/symbol/ALKS' title='Alkermes plc'>ALKS</a> <font color=\"red\">-2.5%</font>); Amphastar Pharmaceuticals (<a href='https://seekingalpha.com/symbol/AMPH' title='Amphastar'>AMPH</a> <font color=\"red\">-2.5%</font>), Pain Therapeutics (<a href='https://seekingalpha.com/symbol/PTIE' title='Pain Therapeutics'>PTIE</a> <font color=\"red\">-0.8%</font>); BioDelivery Sciences (<a href='https://seekingalpha.com/symbol/BDSI' title='BioDelivery Sciences International, Inc.'>BDSI</a> <font color=\"red\">-4.9%</font>); Assertio Therapeutics (<a href='https://seekingalpha.com/symbol/ASRT' title='Assertio Therapeutics Inc'>ASRT</a> <font color=\"red\">-6.7%</font>); Nektar Therapeutics (<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color=\"red\">-0.6%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3439562\" data-linked=\"Painkiller stocks in the red on possible Purdue bankruptcy\" data-tweet=\"$ENDP $NSYS $MYL - Painkiller stocks in the red on possible Purdue bankruptcy https://seekingalpha.com/news/3439562-painkiller-stocks-in-red-on-possible-purdue-bankruptcy?source=tweet\" data-url=\"https://seekingalpha.com/news/3439562-painkiller-stocks-in-red-on-possible-purdue-bankruptcy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>68&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439584\" data-ts=\"1551726942\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGRX\" target=\"_blank\">AGRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439584-agile-therapeutics-up-21-on-7_8m-capital-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agile Therapeutics up 21% on $7.8M capital raise</a></h4><ul><li>Thinly traded nano cap Agile Therapeutics (<a href='https://seekingalpha.com/symbol/AGRX' title='Agile Therapeutics, Inc.'>AGRX</a> <font color=\"green\">+20.8%</font>) is up on a 7x surge in volume on the heels of its <a href=\"https://seekingalpha.com/pr/17431293-agile-therapeutics-announces-7_8-million-private-placement\" target=\"_blank\">private placemen</a>t of ~8.4M shares of common stock at $0.93 per share yielding gross proceeds of ~$7.8M.</li><li>Shares are slowly clawing back after plunging 76% in May 2018 when it received a <a href=\"https://seekingalpha.com/news/3357949-agile-therapeutics-76-percent-additional-work-needed-u-s-approval-twirla\" target=\"_blank\">second CRL</a> from the FDA regarding its Twirla contraceptive patch application.</li><li>It recently <a href=\"https://seekingalpha.com/news/3422235-agile-therapeutics-advancing-twirla-refile-u-s-marketing-application-next-quarter\" target=\"_blank\">completed </a>a successful comparative wear study and expects to file an application for the third time next quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439584\" data-linked=\"Agile Therapeutics up 21% on $7.8M capital raise\" data-tweet=\"$AGRX - Agile Therapeutics up 21% on $7.8M capital raise https://seekingalpha.com/news/3439584-agile-therapeutics-up-21-on-7_8m-capital-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3439584-agile-therapeutics-up-21-on-7_8m-capital-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439583\" data-ts=\"1551726889\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XLNX\" target=\"_blank\">XLNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439583-xilinx-cancels-evercore-roadshow-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xilinx cancels Evercore roadshow (update)</a></h4><ul><li>Xilinx (NASDAQ:<a href='https://seekingalpha.com/symbol/XLNX' title='Xilinx, Inc.'>XLNX</a>) has canceled from a non-deal roadshow with Evercore tomorrow, according to Bloomberg sources.</li><li>Headlines only for now and Xilinx hasn't commented on the matter.</li><li>XLNX shares are <font color=\"red\">down 3.8%</font> today after opening lower on this morning's <a href=\"https://seekingalpha.com/news/3439395-bmo-downgrades-xilinx-risk-reward\" target=\"_blank\">BMO downgrade</a>.</li><li>Update: Xilinx confirms the roadshow cancelation citing a \"calendar conflict.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3439583\" data-linked=\"Xilinx cancels Evercore roadshow (update)\" data-tweet=\"$XLNX - Xilinx cancels Evercore roadshow (update) https://seekingalpha.com/news/3439583-xilinx-cancels-evercore-roadshow-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3439583-xilinx-cancels-evercore-roadshow-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439581\" data-ts=\"1551726361\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439581-key-energy-services-leads-energy-materials-gainers-fmc-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Key Energy Services leads Energy/Materials gainers; FMC leads the losers</a></h4><ul><li><b>Gainers: </b>Key Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/KEG' title='Key Energy Services, Inc.'>KEG</a>) <font color=\"green\">+34%</font>. Phunware (NASDAQ:<a href='https://seekingalpha.com/symbol/PHUN' title='Phunware, Inc.'>PHUN</a>) <font color=\"green\">+17%</font>. Arcadia Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a>) <font color=\"green\">+12%</font>. NextDecade (NASDAQ:<a href='https://seekingalpha.com/symbol/NEXT' title='NextDecade Corporation'>NEXT</a>) <font color=\"green\">+7%</font>. Nabors Industries (NYSE:<a href='https://seekingalpha.com/symbol/NBR' title='Nabors Industries Ltd.'>NBR</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>FMC (NYSE:<a href='https://seekingalpha.com/symbol/FMC' title='FMC Corporation'>FMC</a>) <font color=\"red\">-14%</font>. Goodrich Petroleum (NYSEMKT:<a href='https://seekingalpha.com/symbol/GDP' title='Goodrich Petroleum Corp.'>GDP</a>) <font color=\"red\">-8%</font>. Torchlight Energy Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/TRCH' title='Torchlight Energy Resources, Inc.'>TRCH</a>) <font color=\"red\">-8%</font>. Bristow Group (NYSE:<a href='https://seekingalpha.com/symbol/BRS' title='Bristow Group Inc.'>BRS</a>) <font color=\"red\">-8%</font>. Basic Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/BAS' title='Basic Energy Services, Inc.'>BAS</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439581\" data-linked=\"Key Energy Services leads Energy/Materials gainers; FMC leads the losers\" data-tweet=\"$KEG $RKDA $NEXT - Key Energy Services leads Energy/Materials gainers; FMC leads the losers https://seekingalpha.com/news/3439581-key-energy-services-leads-energy-materials-gainers-fmc-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3439581-key-energy-services-leads-energy-materials-gainers-fmc-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439578\" data-ts=\"1551725974\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/POFNF\" target=\"_blank\">POFNF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439578-power-financial-great-west-lifeco-to-buy-back-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Power Financial, Great-West Lifeco to buy back shares</a></h4><ul><li>Power Financial (<a href='https://seekingalpha.com/symbol/POFNF' title='Power Financial Corp.A'>OTCPK:POFNF</a>) <font color=\"green\">gains 1.9%</font> after announcing a<a href=\"https://seekingalpha.com/pr/17431051-power-financial-announces-intention-repurchase-1_65-billion-common-shares-substantial-issuer\" target=\"_blank\"> plan to repurchase </a>for cancellation as much as C$1.65B (US$1.24B) of its common shares through a modified Dutch auction.</li><li>Meanwhile Great-West Lifeco (<a href='https://seekingalpha.com/symbol/GWLOF' title='Great-West Lifeco, Inc.'>OTC:GWLOF</a>), a subsidiary of Power Financial, plans to conduct a substantial issuer bid for up to C$2B of its common shares.</li><li>Power Financial plans to participate in the Great-West offer by tendering a significant portion of its Great-West shares; as a result Power Financial expects its Great-West stake to be marginally reduced.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3425582-great-west-lifeco-sell-unit-1_2b-deal\" target=\"_blank\">Great-West Lifeco to sell unit in $1.2B deal</a> (Jan. 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439578\" data-linked=\"Power Financial, Great-West Lifeco to buy back shares\" data-tweet=\"$POFNF $GWLOF - Power Financial, Great-West Lifeco to buy back shares https://seekingalpha.com/news/3439578-power-financial-great-west-lifeco-to-buy-back-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3439578-power-financial-great-west-lifeco-to-buy-back-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439568\" data-ts=\"1551724051\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439568-senate-committee-looking-high-insulin-prices\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Senate committee &quot;looking into&quot; high insulin prices</a></h4><ul><li>Eli Lilly's (<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color=\"red\">-1.6%</font>) planned launch of a lower-priced insulin, branded as Insulin Lispro, has apparently not assuaged the U.S. Senate Finance Committee's interest with high drug prices.</li><li>In a <a href=\"https://twitter.com/ChuckGrassley?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor\" target=\"_blank\">tweet</a>, Chairman Chuck Grassley (R-IA) says the cheaper insulin is \"only one piece of the puzzle\" and more needs to done considering that insulin has been available for many years. His committee has sent letters to insulin makers requesting information about their pricing practices.</li><li>Related tickers: Sanofi (<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a> <font color=\"green\">+0.6%</font>), Novo Nordisk (<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a> <font color=\"red\">-0.8%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439568\" data-linked=\"Senate committee &quot;looking into&quot; high insulin prices\" data-tweet=\"$LLY $SNY $NVO - Senate committee &quot;looking into&quot; high insulin prices https://seekingalpha.com/news/3439568-senate-committee-looking-high-insulin-prices?source=tweet\" data-url=\"https://seekingalpha.com/news/3439568-senate-committee-looking-high-insulin-prices\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439557\" data-ts=\"1551722612\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439557-eas-apex-legends-races-to-50m-player-mark\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EA&#39;s &#39;Apex Legends&#39; races to 50M-player mark</a></h4><ul>   <li>In its latest milestone, battle-royale videogame <i>Apex Legends</i> (<a href=\"http://seekingalpha.com/symbol/EA\" target=\"_blank\">EA</a> <font color=\"red\">-1.1%</font>) has hit 50M players in less than 30 days of release.</li>    <li>That's faster than segment leader <i>Fortnite,</i> which took about 100 days to hit 45M players. <i>Fortnite</i> currently has more than 200M players and reached a concurrent-player record of 10.7M on Feb. 2.</li>    <li><i>Apex Legends</i> is preparing for its next step in competing with its rival, with its first season ahead along with the debut of its battle pass.</li>    <li><i>Fortnite</i> is owned by Epic Games, which is 40% owned by Tencent (<a href=\"http://seekingalpha.com/symbol/TCEHY\" target=\"_blank\">TCEHY</a> <font color=\"green\">+1.7%</font>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3439557\" data-linked=\"EA&#39;s &#39;Apex Legends&#39; races to 50M-player mark\" data-tweet=\"$EA $TCEHY - EA&#39;s &#39;Apex Legends&#39; races to 50M-player mark https://seekingalpha.com/news/3439557-eas-apex-legends-races-to-50m-player-mark?source=tweet\" data-url=\"https://seekingalpha.com/news/3439557-eas-apex-legends-races-to-50m-player-mark\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439553\" data-ts=\"1551721952\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HCSG\" target=\"_blank\">HCSG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439553-healthcare-services-group-down-9-on-10-k-delay\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare Services Group down 9% on 10-K delay</a></h4><ul><li>Healthcare Services Group (<a href='https://seekingalpha.com/symbol/HCSG' title='Healthcare Services Group, Inc.'>HCSG</a> <font color=\"red\">-8.6%</font>) is down on 25% higher volume in reaction to its <a href=\"https://www.sec.gov/Archives/edgar/data/731012/000073101219000037/a20198k-nt.htm\" target=\"_blank\">disclosure </a>that it will be late filing its 2018 10-K due to an SEC inquiry into its EPS calculation practices. It received a subpoena from the agency a year ago requesting information and documents related to the matter.</li><li>The company says it launched an internal investigation last quarter to ferret out the issue.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439553\" data-linked=\"Healthcare Services Group down 9% on 10-K delay\" data-tweet=\"$HCSG - Healthcare Services Group down 9% on 10-K delay https://seekingalpha.com/news/3439553-healthcare-services-group-down-9-on-10-k-delay?source=tweet\" data-url=\"https://seekingalpha.com/news/3439553-healthcare-services-group-down-9-on-10-k-delay\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439554\" data-ts=\"1551721952\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439554-china-internet-nationwide-financial-services-leads-financial-gainers-enstar-group-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Internet Nationwide Financial Services leads financial gainers; Enstar Group and Hexindai among losers</a></h4><ul><li><b>Gainers:</b> China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"green\">+53%</font>. Jupai Holdings (NYSE:<a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings'>JP</a>) <font color=\"green\">+17%</font>. China Bat Group (NASDAQ:<a href='https://seekingalpha.com/symbol/GLG' title='China Commercial Credit, Inc.'>GLG</a>) <font color=\"green\">+10%</font>. Leju Holdings (NYSE:<a href='https://seekingalpha.com/symbol/LEJU' title='Leju Holdings Limited'>LEJU</a>) <font color=\"green\">+5%</font>. Washington Real Estate Investment Trust (NYSE:<a href='https://seekingalpha.com/symbol/WRE' title='Washington Real Estate Investment'>WRE</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers:</b> Maiden Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MHLD' title='Maiden Hldgs Ltd'>MHLD</a>) <font color=\"red\">-15%</font>. Enstar Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ESGR' title='Enstar Group Limited'>ESGR</a>) <font color=\"red\">-8%</font>. Medley Management (NYSE:<a href='https://seekingalpha.com/symbol/MDLY' title='Medley Management'>MDLY</a>) <font color=\"red\">-6%</font>. Hexindai (NASDAQ:<a href='https://seekingalpha.com/symbol/HX' title='Hexindai Inc.'>HX</a>) <font color=\"red\">-6%</font>. Goosehead Insurance (NASDAQ:<a href='https://seekingalpha.com/symbol/GSHD' title='Goosehead Insurance'>GSHD</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439554\" data-linked=\"China Internet Nationwide Financial Services leads financial gainers; Enstar Group and Hexindai among losers\" data-tweet=\"$CIFS $JP $GLG - China Internet Nationwide Financial Services leads financial gainers; Enstar Group and Hexindai among losers https://seekingalpha.com/news/3439554-china-internet-nationwide-financial-services-leads-financial-gainers-enstar-group-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3439554-china-internet-nationwide-financial-services-leads-financial-gainers-enstar-group-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439547\" data-ts=\"1551721350\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439547-midday-movers-and-shakers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday movers and shakers</a></h4><ul><li><strong>Gainers:</strong> Nightstar Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NITE' title='Nightstar Therapeutics plc'>NITE</a>) <font color=\"green\">+66%</font>. China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"green\">+64%</font>. Ascendis Pharma A/S (NASDAQ:<a href='https://seekingalpha.com/symbol/ASND' title='Ascendis Pharma'>ASND</a>) <font color=\"green\">+62%</font>. China Finance Online (NASDAQ:<a href='https://seekingalpha.com/symbol/JRJC' title='China Finance Online Co. Limited'>JRJC</a>) <font color=\"green\">+46%</font>. Phunware (NASDAQ:<a href='https://seekingalpha.com/symbol/PHUN' title='Phunware, Inc.'>PHUN</a>) <font color=\"green\">+23%</font>. Key Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/KEG' title='Key Energy Services, Inc.'>KEG</a>) <font color=\"green\">+20%</font>. Benitec Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/BNTC' title='Benitec'>BNTC</a>) <font color=\"green\">+19%</font>. Bluegreen Vacations Corporation (NYSE:<a href='https://seekingalpha.com/symbol/BXG' title='Bluegreen Vacations Corp.'>BXG</a>) <font color=\"green\">+18%</font>. Alphatec Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/ATEC' title='Alphatec Holdings, Inc.'>ATEC</a>) <font color=\"green\">+17%</font>. Jupai Holdings (NYSE:<a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings'>JP</a>) <font color=\"green\">+17%</font>. <strong></strong></li><li><strong>Losers: </strong>Evoke Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a>) <font color=\"red\">-59%</font>. NantHealth e(NASDAQ:<a href='https://seekingalpha.com/symbol/NH' title='NantHealth'>NH</a>) <font color=\"red\">-20%</font>. Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"red\">-16%</font>. Intrexon Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a>) <font color=\"red\">-15%</font>. Maiden Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MHLD' title='Maiden Hldgs Ltd'>MHLD</a>) <font color=\"red\">-15%</font>. FMC Corporation (NYSE:<a href='https://seekingalpha.com/symbol/FMC' title='FMC Corporation'>FMC</a>) <font color=\"red\">-14%</font>. Endo International (NASDAQ:<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a>) <font color=\"red\">-14%</font>. Social Reality (NASDAQ:<a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a>) <font color=\"red\">-15%</font>. AAC Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AAC' title='AAC Holdings, Inc.'>AAC</a>) <font color=\"red\">-12%</font>. Fortress Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/FBIO' title='Fortress Biotech, Inc.'>FBIO</a>) <font color=\"red\">-11%</font>.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3439547\" data-linked=\"Midday movers and shakers\" data-tweet=\"$NITE $CIFS $ASND - Midday movers and shakers https://seekingalpha.com/news/3439547-midday-movers-and-shakers?source=tweet\" data-url=\"https://seekingalpha.com/news/3439547-midday-movers-and-shakers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439546\" data-ts=\"1551721319\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPMX\" target=\"_blank\">BPMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439546-biopharmx-completes-enrollment-in-mid-stage-study-of-bpxminus-04-in-rosacea-shares-up-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioPharmX completes enrollment in mid-stage study of BPX-04 in rosacea; shares up 7%</a></h4><ul><li>BioPharmX (<a href='https://seekingalpha.com/symbol/BPMX' title='BioPharmX Corporation'>BPMX</a> <font color=\"green\">+6.7%</font>) has completed enrollment of 207 subjects in a <a href=\"https://clinicaltrials.gov/ct2/show/NCT03667222?lead=biopharmx&amp;phase=1&amp;rank=1\" target=\"_blank\">Phase 2b clinical trial</a> evaluating topical minocycline gel BPX-04 in patients with moderate-to-severe <a href=\"https://www.rosacea.org/tags/papulopustular-rosacea\" target=\"_blank\">papulopustular rosacea</a>, a skin condition characterized by acne-like breakouts.</li><li>The randomized study will assess the safety and effectiveness of once-daily BPX-04 over a 12-week treatment period. The primary endpoint is the mean change in the number of facial inflammatory lesions from baseline at week 12 versus vehicle (placebo).</li></ul><div class=\"tiny-share-widget\" data-id=\"3439546\" data-linked=\"BioPharmX completes enrollment in mid-stage study of BPX-04 in rosacea; shares up 7%\" data-tweet=\"$BPMX - BioPharmX completes enrollment in mid-stage study of BPX-04 in rosacea; shares up 7% https://seekingalpha.com/news/3439546-biopharmx-completes-enrollment-in-mid-stage-study-of-bpxminus-04-in-rosacea-shares-up-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3439546-biopharmx-completes-enrollment-in-mid-stage-study-of-bpxminus-04-in-rosacea-shares-up-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439545\" data-ts=\"1551720739\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439545-u-s-stocks-sink-shrugging-off-trade-deal-optimism\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S stocks sink, shrugging off trade deal optimism</a></h4><ul><li>The three major U.S. stock averages wilt, wiping out a strong open, as optimism over a U.S.-China trade deal is offset by hurdles that still remain to reach an agreement, the S&amp;P hitting a key resistance level, and lower construction in December.</li><li>S&amp;P<font color=\"red\"> falls 1.0%</font>, Nasdaq <font color=\"red\">-1.0%</font>, Dow<font color=\"red\"> -1.3%</font>. If the Dow remains at that level, it represents the biggest percentage decline since Jan. 3.</li><li>All 11 S&amp;P 500 industry sectors sink into the red, with health care (<font color=\"red\">-1.5%</font>) and IT (<font color=\"red\">-0.9%</font>) dragging the most.</li><li>Among notable decliners: UnitedHealth (<font color=\"red\">-3.4%</font>), CVS (<font color=\"red\">-2.7%</font>), Humana (<font color=\"red\">-4.5%</font>), Adobe Systems (<font color=\"red\">-3.4%</font>), Salesforce.com (<font color=\"red\">-5.0%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3439545\" data-linked=\"U.S stocks sink, shrugging off trade deal optimism\" data-tweet=\"U.S stocks sink, shrugging off trade deal optimism https://seekingalpha.com/news/3439545-u-s-stocks-sink-shrugging-off-trade-deal-optimism?source=tweet\" data-url=\"https://seekingalpha.com/news/3439545-u-s-stocks-sink-shrugging-off-trade-deal-optimism\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439542\" data-ts=\"1551720455\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VOD\" target=\"_blank\">VOD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439542-bloomberg-vodafone-plans-3b-convertible-bond-sale-sharesminus-2_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: Vodafone plans \u20ac3B convertible bond sale; shares -2.8%</a></h4><ul>   <li>Vodafone (NASDAQ:<a href='https://seekingalpha.com/symbol/VOD' title='Vodafone Group Plc'>VOD</a>) took a sudden dip on a Bloomberg headline that it's planning a \u20ac3B convertible bond sale.</li>    <li>That sale could come as soon as tomorrow, according to the report.</li>    <li>Shares are <font color=\"red\">down 2.8%</font> currently in U.S. trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439542\" data-linked=\"Bloomberg: Vodafone plans \u20ac3B convertible bond sale; shares -2.8%\" data-tweet=\"$VOD - Bloomberg: Vodafone plans \u20ac3B convertible bond sale; shares -2.8% https://seekingalpha.com/news/3439542-bloomberg-vodafone-plans-3b-convertible-bond-sale-sharesminus-2_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3439542-bloomberg-vodafone-plans-3b-convertible-bond-sale-sharesminus-2_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439532\" data-ts=\"1551718199\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439532-vuzix-leads-consumer-gainers-dean-foods-and-avon-products-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vuzix leads consumer gainers; Dean Foods and Avon Products among losers</a></h4><ul><li><b>Gainers:</b> Vuzix (NASDAQ:<a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corp'>VUZI</a>) <font color=\"green\">+20%</font>. Planet Green Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLAG' title='Planet Green Holdings Corp'>PLAG</a>) <font color=\"green\">+14%</font>. China Automotive Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CAAS' title='China Automotive Systems, Inc.'>CAAS</a>) <font color=\"green\">+12%</font>. Fuwei Films (NASDAQ:<a href='https://seekingalpha.com/symbol/FFHL' title='Fuwei Films &#40;Holdings&#41; Co., Ltd.'>FFHL</a>) <font color=\"green\">+9%</font>. SunOpta (NASDAQ:<a href='https://seekingalpha.com/symbol/STKL' title='SunOpta, Inc.'>STKL</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers:</b> Sequential Brands Group (NASDAQ:<a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a>) <font color=\"red\">-9%</font>. Dean Foods (NYSE:<a href='https://seekingalpha.com/symbol/DF' title='Dean Foods Company'>DF</a>) <font color=\"red\">-8%</font>. New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) <font color=\"red\">-7%</font>. Avon Products (NYSE:<a href='https://seekingalpha.com/symbol/AVP' title='Avon Products, Inc.'>AVP</a>) <font color=\"red\">-7%</font>. Electrameccanica Vehicles (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLO' title='Electrameccanica Vehicles Corp. Ltd.'>SOLO</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439532\" data-linked=\"Vuzix leads consumer gainers; Dean Foods and Avon Products among losers\" data-tweet=\"$VUZI $PLAG $CAAS - Vuzix leads consumer gainers; Dean Foods and Avon Products among losers https://seekingalpha.com/news/3439532-vuzix-leads-consumer-gainers-dean-foods-and-avon-products-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3439532-vuzix-leads-consumer-gainers-dean-foods-and-avon-products-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439530\" data-ts=\"1551717753\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPY\" target=\"_blank\">SPY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439530-s-and-p-drops-after-hitting-key-resistance-level\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">S&amp;P drops after hitting key resistance level</a></h4><ul><li>S&amp;P now -0.5%, down more than 1% from its overnight high.</li><li>Bears needed 2817 (Oct. 17 high) to hold; the next resistance after that would have been in the 2870s.</li><li>The 10-day moving-average (2,789), which has held since early January, is within spitting distance.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439530\" data-linked=\"S&amp;P drops after hitting key resistance level\" data-tweet=\"$SPY $SP500 - S&amp;P drops after hitting key resistance level https://seekingalpha.com/news/3439530-s-and-p-drops-after-hitting-key-resistance-level?source=tweet\" data-url=\"https://seekingalpha.com/news/3439530-s-and-p-drops-after-hitting-key-resistance-level\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439526\" data-ts=\"1551716720\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439526-childrens-placeminus-9-and-cartersminus-3-amid-clearance-woes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Children&#39;s Place -9% and Carter&#39;s -3% amid clearance woes</a></h4><ul><li>Children's Place (<a href='https://seekingalpha.com/symbol/PLCE' title='The Children&#39;s Place Retail Stores, Inc.'>PLCE</a> <font color=\"red\">-8.9%</font>) CEO Janes Elfers says a widespread clearing out of inventory ahead of the Gymboree closeout cost the company $0.79 in EPS during the quarter.</li><li>The company is also expecting a rough Q2 before the benefits of reduced competition start to be felt.</li><li>The weak Q1 from PLCE has also sent Carter's (<a href='https://seekingalpha.com/symbol/CRI' title='Carter&#39;s, Inc.'>CRI</a> <font color=\"red\">-2.7%</font>) lower on some of the same concerns.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439393-comp-sales-childrens-place\" target=\"_blank\">Comp sales down at Children's Place</a> (March 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439526\" data-linked=\"Children&#39;s Place -9% and Carter&#39;s -3% amid clearance woes\" data-tweet=\"$PLCE $CRI - Children&#39;s Place -9% and Carter&#39;s -3% amid clearance woes https://seekingalpha.com/news/3439526-childrens-placeminus-9-and-cartersminus-3-amid-clearance-woes?source=tweet\" data-url=\"https://seekingalpha.com/news/3439526-childrens-placeminus-9-and-cartersminus-3-amid-clearance-woes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439525\" data-ts=\"1551716526\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRNB\" target=\"_blank\">PRNB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439525-principia-bios-lead-candidate-successful-in-mid-stage-pemphigus-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Principia Bio&#39;s lead candidate successful in mid-stage pemphigus study</a></h4><ul><li>Thinly traded Principia Biopharma (<a href='https://seekingalpha.com/symbol/PRNB' title='Principia Biopharma'>PRNB</a> <font color=\"green\">+1.1%</font>) is up, albeit on turnover of only 5K shares, following its <a href=\"https://seekingalpha.com/pr/17430901-principia-biopharma-announces-positive-data-phase-2-pemphigus-vulgaris-trial-2019-american\" target=\"_blank\">announcement </a>of positive results from an open-label <a href=\"https://clinicaltrials.gov/ct2/show/NCT02704429?lead=principia&amp;phase=1&amp;rank=1\" target=\"_blank\">Phase 2 clinical trial</a> evaluating its lead candidate, Orphan Drug-tagged PRN1008, in pemphigus patients. The data were presented at the American Academy of Dermatology Annual Meeting in Washington, DC.</li><li>The study met the primary efficacy endpoint of a statistically valid proportion of patients who achieved control of disease activity &#40;CDA&#41; at week 4 with low-dose corticosteroids. Specifically, 54% of subjects in the treatment group met the endpoint while 73% achieved CDA at week 12.</li><li>On the safety front, the most frequent treatment-related adverse events were nausea (15%), abdominal pain (11%) and headache (11%).</li><li>Topline results from a Phase 2 extension study should be available in Q4.</li><li>A randomized Phase 3 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03762265?lead=principia&amp;phase=2&amp;rank=1\" target=\"_blank\">PEGASUS</a>, is currently recruiting patients.</li><li><a href=\"https://www.mayoclinic.org/diseases-conditions/pemphigus/symptoms-causes/syc-20350404\" target=\"_blank\">Pemphigus </a>is a rare autoimmune disorder characterized by skin blisters.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439525\" data-linked=\"Principia Bio&#39;s lead candidate successful in mid-stage pemphigus study\" data-tweet=\"$PRNB - Principia Bio&#39;s lead candidate successful in mid-stage pemphigus study https://seekingalpha.com/news/3439525-principia-bios-lead-candidate-successful-in-mid-stage-pemphigus-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3439525-principia-bios-lead-candidate-successful-in-mid-stage-pemphigus-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439521\" data-ts=\"1551715402\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439521-alphatec-and-ascendis-pharma-among-healthcare-gainers-intrexon-and-ohr-pharmaceutical-among\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alphatec and Ascendis Pharma among healthcare gainers; Intrexon and OHR Pharmaceutical among the losers</a></h4><ul><li><b>Gainers: </b>Nightstar Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NITE' title='Nightstar Therapeutics plc'>NITE</a>) <font color=\"green\">+66%</font>. Ascendis Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ASND' title='Ascendis Pharma'>ASND</a>) <font color=\"green\">+64%</font>. Benitec Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/BNTC' title='Benitec'>BNTC</a>) <font color=\"green\">+20%</font>. Arsanis (NASDAQ:<a href='https://seekingalpha.com/symbol/ASNS' title='Arsanis, Inc.'>ASNS</a>) <font color=\"green\">+12%</font>. Alphatec (NASDAQ:<a href='https://seekingalpha.com/symbol/ATEC' title='Alphatec Holdings, Inc.'>ATEC</a>) <font color=\"green\">+11%</font>.</li><li><b>Losers: </b>Evoke Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a>) <font color=\"red\">-60%</font>. OHR Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/OHRP' title='Ohr Pharmaceutical, Inc.'>OHRP</a>) <font color=\"red\">-10%</font>. Intrexon (NASDAQ:<a href='https://seekingalpha.com/symbol/XON' title='Intrexon Corp'>XON</a>) <font color=\"red\">-10%</font>. OpGen (NASDAQ:<a href='https://seekingalpha.com/symbol/OPGN' title='OpGen'>OPGN</a>) <font color=\"red\">-9%</font>. Endo International (NASDAQ:<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a>) <font color=\"red\">-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439521\" data-linked=\"Alphatec and Ascendis Pharma among healthcare gainers; Intrexon and OHR Pharmaceutical among the losers\" data-tweet=\"$NITE $ASND $BNTC - Alphatec and Ascendis Pharma among healthcare gainers; Intrexon and OHR Pharmaceutical among the losers https://seekingalpha.com/news/3439521-alphatec-and-ascendis-pharma-among-healthcare-gainers-intrexon-and-ohr-pharmaceutical-among?source=tweet\" data-url=\"https://seekingalpha.com/news/3439521-alphatec-and-ascendis-pharma-among-healthcare-gainers-intrexon-and-ohr-pharmaceutical-among\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439520\" data-ts=\"1551715072\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPNE\" target=\"_blank\">SPNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439520-seaspine-files-for-150m-mixed-shelf-offering-shares-down-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SeaSpine files for $150M mixed shelf offering; shares down 3%</a></h4><ul><li>SeaSpine Holdings (<a href='https://seekingalpha.com/symbol/SPNE' title='SeaSpine Holdings Corporation'>SPNE</a> <font color=\"red\">-2.7%</font>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1637761/000163776119000050/s-32019atmregistrationstat.htm\" target=\"_blank\">prospectus </a>for a $150M mixed shelf offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439520\" data-linked=\"SeaSpine files for $150M mixed shelf offering; shares down 3%\" data-tweet=\"$SPNE - SeaSpine files for $150M mixed shelf offering; shares down 3% https://seekingalpha.com/news/3439520-seaspine-files-for-150m-mixed-shelf-offering-shares-down-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3439520-seaspine-files-for-150m-mixed-shelf-offering-shares-down-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439518\" data-ts=\"1551714919\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CISN\" target=\"_blank\">CISN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439518-cisionplus-7_3-on-report-considering-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cision +7.3% on report it&#39;s considering sale</a></h4><ul>   <li>Cision (NYSE:<a href='https://seekingalpha.com/symbol/CISN' title='Cision Ltd.'>CISN</a>) has <font color=\"green\">jumped 7.3%</font> on a Reuters report that it's <a href=\"https://www.reuters.com/article/us-cision-m-a-exclusive/exclusive-pr-newswire-owner-cision-explores-sale-sources-idUSKCN1QL1MF\" target=\"_blank\">considering a sale of the company</a>.</li>    <li>Cision is already part-owned by private equity (by GTCR), and it's talking with other P-E firms to explore a sale, Reuters says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439518\" data-linked=\"Cision +7.3% on report it&#39;s considering sale\" data-tweet=\"$CISN - Cision +7.3% on report it&#39;s considering sale https://seekingalpha.com/news/3439518-cisionplus-7_3-on-report-considering-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3439518-cisionplus-7_3-on-report-considering-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439514\" data-ts=\"1551714647\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRNA\" target=\"_blank\">VRNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439514-verona-up-4-on-positive-ensifentrine-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verona up 4% on positive ensifentrine data</a></h4><ul><li>Ultra-thinly traded Verona Pharma plc (<a href='https://seekingalpha.com/symbol/VRNA' title='Verona Pharma plc'>VRNA</a> <font color=\"green\">+4.2%</font>) is up on triple normal volume, albeit on turnover of only 24K shares, on the heels of encouraging <a href=\"https://seekingalpha.com/pr/17430987-verona-pharma-reports-positive-interim-data-ensifentrine-dry-powder-inhaler-formulation-first\" target=\"_blank\">preliminary data</a> from the first part of a two-part <a href=\"https://clinicaltrials.gov/ct2/show/NCT03673670?lead=verona&amp;phase=1&amp;rank=1\" target=\"_blank\">Phase 2 clinical trial</a> evaluating a dry powder inhaler &#40;DPI&#41; formulation of ensifentrine (RPL554) in patients with moderate-to-severe chronic obstructive pulmonary disease &#40;COPD&#41;.</li><li>Patients receiving a single dose of one of five strengths of ensifentrine DPI showed statistically significant and clinically meaningful increases in lung function versus placebo as measured by forced expiratory volume in one second (FEV<sub>1</sub>) (the amount the patient can exhale in one second). </li><li>The second part of the study assessing the candidate for one week of twice-daily doses is next up. Participants will be randomized to receive one of four dose levels or placebo. The primary endpoint will again be peak FEV<sub>1</sub> levels. </li><li>Ensifentrine is a bronchodilator that inhibits two enzymes called phosphodiesterase 3 and 4. It is also being developed to treat cystic fibrosis and asthma.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439514\" data-linked=\"Verona up 4% on positive ensifentrine data\" data-tweet=\"$VRNA - Verona up 4% on positive ensifentrine data https://seekingalpha.com/news/3439514-verona-up-4-on-positive-ensifentrine-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3439514-verona-up-4-on-positive-ensifentrine-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439516\" data-ts=\"1551714404\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KR\" target=\"_blank\">KR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439516-baml-positive-on-kroger-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BAML positive on Kroger ahead of earnings</a></h4><ul> <li>Bank of America Merrill Lynch is positive on Kroger (<a href='https://seekingalpha.com/symbol/KR' title='Kroger Co.'>KR</a> <font color='green'>+1.7%</font>) ahead of the company's earnings report this week. The firm also sees an overreaction to the potential of a new grocery chain from Amazon.</li> <li>\"We note that AMZN is focused on large cities like LA, San Francisco, Seattle, etc., where KR has a more limited presence. Additionally KR has a long history of competing with strong discount players (incl. WMT, DG, COST, &amp; Aldi) and maintaining aggressive price positioning,\" notes the BAML analyst team.</li> <li>Looking ahead, BAML calls the risk-reward profile on Kroger favorable due to the digital outlook, the expected benefits of the Ocado partnership over the next 5 years and the development of a potentially highly profitable ecosystem supported by Restock initiatives.</li> <li>The analyst team keeps a Buy rating and price target of $37 (30% upside) on KR in place.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439516\" data-linked=\"BAML positive on Kroger ahead of earnings\" data-tweet=\"$KR - BAML positive on Kroger ahead of earnings https://seekingalpha.com/news/3439516-baml-positive-on-kroger-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3439516-baml-positive-on-kroger-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439515\" data-ts=\"1551713974\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439515-cirrus-wins-knowles-loses-in-galaxy-s10-susquehanna\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cirrus wins, Knowles loses in Galaxy S10 - Susquehanna</a></h4><ul><li>Susquehanna says Cirrus Logic (<a href='https://seekingalpha.com/symbol/CRUS' title='Cirrus Logic, Inc.'>CRUS</a> <font color='green'>+1.2%</font>) could benefit from Samsung's Galaxy S10 phone with a recent teardown showing the device includes two CRUS amps.</li><li>The Galaxy S9 used audio amps from Maxim (<a href='https://seekingalpha.com/symbol/MXIM' title='Maxim Integrated Products, Inc.'>MXIM</a> <font color='green'>+0.9%</font>).</li><li>Susquehanna: \"We estimate that amplifiers at Samsung represent an ~$200 million opportunity (400 million amplifiers at $0.50 each), which is currently largely untapped by Cirrus.\"</li><li>Cirrus reportedly gets about 3% of its revenue from Samsung compared to the 80% from Apple's iPhones, where Susquehanna sees a $300M opportunity with 200M handsets with three amps at $0.50 each.</li><li>The firm calls Knowles (<a href='https://seekingalpha.com/symbol/KN' title='Knowles Corporation'>KN</a> <font color='red'>-0.7%</font>) a \"big loser\" with the S10 since prior models mostly used KN's microphone MEMS while the S10 uses two GoerTek microphones.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439515\" data-linked=\"Cirrus wins, Knowles loses in Galaxy S10 - Susquehanna\" data-tweet=\"$CRUS $MXIM $KN - Cirrus wins, Knowles loses in Galaxy S10 - Susquehanna https://seekingalpha.com/news/3439515-cirrus-wins-knowles-loses-in-galaxy-s10-susquehanna?source=tweet\" data-url=\"https://seekingalpha.com/news/3439515-cirrus-wins-knowles-loses-in-galaxy-s10-susquehanna\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439513\" data-ts=\"1551713798\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439513-motorola-solutions-sierra-wireless-team-on-public-safety-vehicle-tech\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Motorola Solutions, Sierra Wireless team on public safety vehicle tech</a></h4><ul>   <li>Motorola Solutions (<a href=\"http://seekingalpha.com/symbol/MSI\" target=\"_blank\">MSI</a> <font color=\"red\">-0.3%</font>) and Sierra Wireless (<a href=\"http://seekingalpha.com/symbol/SWIR\" target=\"_blank\">SWIR</a> <font color=\"green\">+1.7%</font>) are teaming up on delivering broadband communications for <a href=\"https://seekingalpha.com/pr/17431410-motorola-solutions-sierra-wireless-provide-broadband-communications-first-responders-road\" target=\"_blank\">first responders in vehicles</a>.</li>    <li>That will include a solution combining Sierra Wireless' AirLink LTE in-vehicle routers and Motorola's products, including the Si500 body-worn cameras and APX two-way radios.</li>    <li>Today, Motorola is offering the AirLink MG90 and MP70 LTE-A Pro routers, which work on any commercial broadband network and are FirstNet Ready, to work with AT&amp;T's first-responder network.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3439513\" data-linked=\"Motorola Solutions, Sierra Wireless team on public safety vehicle tech\" data-tweet=\"$MSI $SWIR - Motorola Solutions, Sierra Wireless team on public safety vehicle tech https://seekingalpha.com/news/3439513-motorola-solutions-sierra-wireless-team-on-public-safety-vehicle-tech?source=tweet\" data-url=\"https://seekingalpha.com/news/3439513-motorola-solutions-sierra-wireless-team-on-public-safety-vehicle-tech\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439512\" data-ts=\"1551713407\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HA\" target=\"_blank\">HA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439512-hawaiian-holdingsminus-7-southwest-starts-selling-tickets-to-hawaii\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hawaiian Holdings -7% as Southwest starts selling tickets to Hawaii</a></h4><ul> <li>Hawaiian Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/HA' title='Hawaiian Holdings, Inc.'>HA</a>) is <font color=\"red\">down 7.22%</font> after Deutsche Bank lowers its rating to Sell from Hold on concerns over the entrance of Southwest into Hawaii. DB drops is price target on the airline stock to $27 from $33.</li> <li>A first look at Southwest's fares into Hawaii shows some peak summer rates of around $200 each way.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3439512\" data-linked=\"Hawaiian Holdings -7% as Southwest starts selling tickets to Hawaii\" data-tweet=\"$HA - Hawaiian Holdings -7% as Southwest starts selling tickets to Hawaii https://seekingalpha.com/news/3439512-hawaiian-holdingsminus-7-southwest-starts-selling-tickets-to-hawaii?source=tweet\" data-url=\"https://seekingalpha.com/news/3439512-hawaiian-holdingsminus-7-southwest-starts-selling-tickets-to-hawaii\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439509\" data-ts=\"1551713018\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRCA\" target=\"_blank\">VRCA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439509-verrica-pharma-up-7-on-positive-lead-candidate-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Verrica Pharma up 7% on positive lead candidate data</a></h4><ul><li>Thinly traded micro cap Verrica Pharmaceuticals (<a href='https://seekingalpha.com/symbol/VRCA' title='Verrica Pharmaceuticals Inc.'>VRCA</a> <font color='green'>+7.2%</font>) is up on below average volume on the heels of <a href=\"https://seekingalpha.com/pr/17430909-verrica-pharmaceuticals-presents-positive-results-two-phase-3-clinical-trials-vpminus-102\" target=\"_blank\">successful results</a> from two Phase 3 clinical trials, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03377790?lead=verrica&amp;phase=2&amp;rank=2\" target=\"_blank\">CAMP-1</a> and <a href=\"https://clinicaltrials.gov/ct2/show/NCT03377803?lead=verrica&amp;phase=2&amp;rank=1\" target=\"_blank\">CAMP-2</a>, evaluating lead candidate VP-102 (cantharidin) for the topical treatment of molluscum contagiosum, a common viral infection characterized by small bumps on the skin. The data were presented at the American Academy of Dermatology Annual Meeting in Washington, DC.</li><li>Both trials met the primary endpoint of a statistically valid proportion of subjects achieving complete skin clearance at day 84. Specifically, 46% of treated patients in CAMP-1 and 54% in CAMP-2 achieved to total skin clearance compared to 18% and 13%, respectively, for placebo (p&lt;0.0001).</li><li>The company plans to file its U.S. marketing application in H2.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439509\" data-linked=\"Verrica Pharma up 7% on positive lead candidate data\" data-tweet=\"$VRCA - Verrica Pharma up 7% on positive lead candidate data https://seekingalpha.com/news/3439509-verrica-pharma-up-7-on-positive-lead-candidate-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3439509-verrica-pharma-up-7-on-positive-lead-candidate-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439508\" data-ts=\"1551713009\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DELL\" target=\"_blank\">DELL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439508-dell-hires-banks-for-fixed-income-calls\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dell hires banks for fixed income calls</a></h4><ul><li>Dell (NYSE:<a href='https://seekingalpha.com/symbol/DELL' title='Dell Technologies Inc.'>DELL</a>) has hired banks to arrange a series of fixed income investor calls on Tuesday, according to Bloomberg sources.</li><li>The banks involved reportedly include Barclays, Bank of America, Citi, Credit Suisse, Goldman Sachs, and JPMorgan.</li><li>Dell shares are <font color=\"red\">down 0.8%</font> to $56.18.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439508\" data-linked=\"Dell hires banks for fixed income calls\" data-tweet=\"$DELL - Dell hires banks for fixed income calls https://seekingalpha.com/news/3439508-dell-hires-banks-for-fixed-income-calls?source=tweet\" data-url=\"https://seekingalpha.com/news/3439508-dell-hires-banks-for-fixed-income-calls\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439495\" data-ts=\"1551711601\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYOK\" target=\"_blank\">MYOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439495-myokardia-up-3-on-positive-mavacamten-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MyoKardia up 3% on positive mavacamten data</a></h4><ul><li>MyoKardia (<a href='https://seekingalpha.com/symbol/MYOK' title='MyoKardia, Inc.'>MYOK</a> <font color=\"green\">+3.4%</font>) is up in early trade in response to <a href=\"https://seekingalpha.com/pr/17431531-myokardia-announces-positive-six-month-safety-efficacy-data-pioneer-ole-study-mavacamten\" target=\"_blank\">positive results</a> from an open-label extension study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03496168?lead=myokardia&amp;rank=2\" target=\"_blank\">PIONEER-OLE</a>, evaluating mavacamten in 13 patients with symptomatic obstructive hypertrophic cardiomyopathy &#40;HCM&#41; who completed the Phase 2 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02842242?lead=myokardia&amp;rank=7\" target=\"_blank\">PIONEER-HCM</a> study. The data will be presented at the American College of Cardiology\u2019s Annual Scientific Sessions in New Orleans on Sunday, March 17.</li><li>Preliminary results showed that treatment with mavacamten produced significant reductions in left ventricle obstruction while preserving left ventricle ejection fraction above normal over a sustained period of time. Significant improvements in symptoms were also observed.</li><li>Mavacamten is an orally available small molecule designed to reduce left ventricular contractility by modulating the function of cardiac myosin, the protein that drives heart muscle contraction.</li><li>HCM is an inherited heart disorder characterized by thickened walls of the heart which prevents the left ventricle from expanding, reducing pumping capacity.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439495\" data-linked=\"MyoKardia up 3% on positive mavacamten data\" data-tweet=\"$MYOK - MyoKardia up 3% on positive mavacamten data https://seekingalpha.com/news/3439495-myokardia-up-3-on-positive-mavacamten-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3439495-myokardia-up-3-on-positive-mavacamten-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439492\" data-ts=\"1551711228\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCD\" target=\"_blank\">MCD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439492-mcdonaldsminus-1-amid-comp-sales-worries\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McDonald&#39;s -1% amid comp sales worries</a></h4><ul> <li>Shares of McDonald's (NYSE:<a href='https://seekingalpha.com/symbol/MCD' title='McDonald&#39;s Corporation'>MCD</a>) are <font color=\"red\">down 0.98%</font> on word that Cleveland Research checks show the restaurant chain underperforming Q1 comparables sales expectations.</li> <li>Some analysts have warned that the harsher winter weather this year across the U.S. has held back restaurant traffic more than anticipated.</li><li>27 of the 42 publicly-traded restaurant stocks with a market cap of over $50M are in negative territory to start the week.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3439492\" data-linked=\"McDonald&#39;s -1% amid comp sales worries\" data-tweet=\"$MCD - McDonald&#39;s -1% amid comp sales worries https://seekingalpha.com/news/3439492-mcdonaldsminus-1-amid-comp-sales-worries?source=tweet\" data-url=\"https://seekingalpha.com/news/3439492-mcdonaldsminus-1-amid-comp-sales-worries\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439486\" data-ts=\"1551710610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGMS\" target=\"_blank\">SGMS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439486-scientific-games-receives-10-year-turkey-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scientific Games receives 10-year Turkey contract</a></h4><ul><li>Scientific Games (NASDAQ:<a href='https://seekingalpha.com/symbol/SGMS' title='Scientific Games Corp'>SGMS</a>) <font color=\"green\">gains 1.2%</font> after its Şans Girişim joint venture <a href=\"https://seekingalpha.com/pr/17431926-scientific-games-joint-venture-wins-10-year-sports-betting-contract-turkey\" target=\"_blank\">receives</a> a 10-year sports betting contract in Turkey.</li><li>The JV is with Sans Digital, an affiliate of one of Turkey's largest companies that has hands in energy, real estate, and media.</li><li>The venture will implement the turnkey national sports betting solution across at least 5,300 retail points-of-sale. Scientific Games will provide the central hardware and software, terminals, maintenance, and a risk management solution.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439486\" data-linked=\"Scientific Games receives 10-year Turkey contract\" data-tweet=\"$SGMS - Scientific Games receives 10-year Turkey contract https://seekingalpha.com/news/3439486-scientific-games-receives-10-year-turkey-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3439486-scientific-games-receives-10-year-turkey-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439484\" data-ts=\"1551710391\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATNX\" target=\"_blank\">ATNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439484-athenex-up-fraction-on-positive-kx2minus-391-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Athenex up a fraction on positive KX2-391 data</a></h4><ul><li>Athenex (<a href='https://seekingalpha.com/symbol/ATNX' title='Athenex, Inc.'>ATNX</a> <font color=\"green\">+0.3%</font>) is up out of the gate this morning in reaction to the <a href=\"https://seekingalpha.com/pr/17431221-athenex-announces-positive-topline-results-two-phase-iii-studies-kx2minus-391-ointment-1\" target=\"_blank\">successful outcomes</a> from two Phase 3 clinical trials evaluating KX2-391 ointment for the treatment of <a href=\"https://www.skincancer.org/skin-cancer-information/actinic-keratosis\" target=\"_blank\">actinic keratosis</a> &#40;AK&#41;, rough scaly skin caused by excess sun exposure. The results were presented at the American Academy of Dermatology Annual Meeting in Washington, DC.</li><li>Both studies met the primary endpoint of a statistically significant proportion of patients achieving 100% clearance of AK lesions at day 57 within the face or scalp treatment areas compared to vehicle (placebo). Specifically, 44% of treated patients in study <a href=\"https://clinicaltrials.gov/ct2/show/NCT03285477?lead=athenex&amp;phase=2&amp;rank=2\" target=\"_blank\">-003</a> and 54% in study <a href=\"https://clinicaltrials.gov/ct2/show/NCT03285490?lead=athenex&amp;phase=2&amp;rank=1\" target=\"_blank\">-004</a> achieved total clearance compared to 5% and 13%, respectively, for control.</li><li>The company plans to review the data with the FDA.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439484\" data-linked=\"Athenex up a fraction on positive KX2-391 data\" data-tweet=\"$ATNX - Athenex up a fraction on positive KX2-391 data https://seekingalpha.com/news/3439484-athenex-up-fraction-on-positive-kx2minus-391-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3439484-athenex-up-fraction-on-positive-kx2minus-391-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439478\" data-ts=\"1551709995\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FL\" target=\"_blank\">FL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439478-foot-lockerplus-2-after-pivotal-research-nod\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Foot Locker +2% after Pivotal Research nod</a></h4><ul> <li>Pivotal Research lifts Foot Locker (<a href='https://seekingalpha.com/symbol/FL' title='Foot Locker, Inc.'>FL</a> <font color='green'>+1.4%</font>) to a Buy rating after having the retailer set at Hold.</li> <li>Foot Locker convinced the Pivotal analyst team with last week's earnings report that it's back on the right path</li> <li>Pivotal sets a price target on Foot Locker of $73, which is well above the 52-week high of $68.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439478\" data-linked=\"Foot Locker +2% after Pivotal Research nod\" data-tweet=\"$FL - Foot Locker +2% after Pivotal Research nod https://seekingalpha.com/news/3439478-foot-lockerplus-2-after-pivotal-research-nod?source=tweet\" data-url=\"https://seekingalpha.com/news/3439478-foot-lockerplus-2-after-pivotal-research-nod\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439476\" data-ts=\"1551709465\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439476-avxl-seel-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AVXL, SEEL among premarket gainers</a></h4><ul><li>Nightstar Therapeutics Plc (NASDAQ:<a href='https://seekingalpha.com/symbol/NITE' title='Nightstar Therapeutics plc'>NITE</a>) <font color=\"green\">+66% </font>on being <a href=\"https://seekingalpha.com/news/3439377-biogen-buy-nightstar-therapeutics-877m\" target=\"_blank\">acquired</a> by Biogen.</li><li>Ascendis Pharma A/S (NASDAQ:<a href='https://seekingalpha.com/symbol/ASND' title='Ascendis Pharma'>ASND</a>) <font color=\"green\">+60%</font> on positive TransCon <a href=\"https://seekingalpha.com/news/3439422-ascendis-pharma-56-percent-premarket-positive-transcon-data\" target=\"_blank\">data</a>.</li><li>China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"green\">+45%</font>.</li><li>Arcadia Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a>) <font color=\"green\">+23% </font>on hemp <a href=\"https://seekingalpha.com/news/3439435-arcadia-26-percent-premarket-hemp-license-hawaii\" target=\"_blank\">license</a> in Hawaii.</li><li>NantKwest (NASDAQ:<a href='https://seekingalpha.com/symbol/NK' title='NantKwest'>NK</a>) <font color=\"green\">+22%</font> on signing worldwide license <a href=\"https://seekingalpha.com/pr/17431397-nantkwest-signs-worldwide-license-agreement-promab-biotechnologies-exclusively-develop-select\" target=\"_blank\">agreement</a> with ProMab biotechnologies.</li><li>Medigus (NASDAQ:<a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd'>MDGS</a>) <font color=\"green\">+21% </font>on <a href=\"https://seekingalpha.com/pr/17431028-medigus-establish-linkury-e-commerce-platform-cbd-products\" target=\"_blank\">entering</a> into a binding memorandum of understanding with Linkury.</li><li>Anavex Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/AVXL' title='Anavex Life Sciences Corp.'>AVXL</a>) <font color=\"green\">+16%. </font></li><li>Cool Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AWSM' title='Cool Holdings Inc.'>AWSM</a>) <font color=\"green\">+15%</font>.</li><li>Xenetic Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a>) <font color=\"green\">+12%</font> on <a href=\"https://seekingalpha.com/news/3439241-xbiotech-13-percent-positive-bermekimab-data\" target=\"_blank\">positive</a> bermekimab data.</li><li>Office Depot (NYSE:<a href='https://seekingalpha.com/symbol/ODP' title='Office Depot Inc.'>ODP</a>) <font color=\"green\">+12% </font>after inking Alibaba <a href=\"https://seekingalpha.com/news/3439414-office-depot-plus-11-percent-inking-alibaba-deal\" target=\"_blank\">deal</a>.</li><li>Luna Innovations (NASDAQ:<a href='https://seekingalpha.com/symbol/LUNA' title='Luna Innovations Incorporated'>LUNA</a>) <font color=\"green\">+10%</font> on <a href=\"https://seekingalpha.com/news/3439385-luna-innovations-reports-q4-results\" target=\"_blank\">Q4 results</a>.</li><li>India Globalization Capital (<a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a>) <font color=\"green\">+7%</font>.</li><li>Sequential Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a>) <font color=\"green\">+7%</font>.</li><li>China Recycling Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/CREG' title='China Recycling Energy Corporation'>CREG</a>) <font color=\"green\">+7%</font>.</li><li>China Ceramics (NASDAQ:<a href='https://seekingalpha.com/symbol/CCCL' title='China Ceramics Co., Ltd.'>CCCL</a>) <font color=\"green\">+6%</font>.</li><li>Sesen Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/SESN' title='Sesen Bio, Inc.'>SESN</a>) <font color=\"green\">+6%</font> on <a href=\"https://seekingalpha.com/news/3439369-sesen-bio-reports-fy-results\" target=\"_blank\">FY earnings</a>.</li><li>Kandi Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a>) <font color=\"green\">+6%</font> after new JV <a href=\"https://seekingalpha.com/news/3439455-kandi-technologies-plus-7-percent-new-jv-deal\" target=\"_blank\">deal</a>.</li><li>Seelos Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SEEL' title='Seelos Therapeutics Inc'>SEEL</a>) <font color=\"green\">+6%</font>.</li><li>Trevena (NASDAQ:<a href='https://seekingalpha.com/symbol/TRVN' title='Trevena, Inc.'>TRVN</a>) <font color=\"green\">+5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439476\" data-linked=\"AVXL, SEEL among premarket gainers\" data-tweet=\"$NITE $ASND $CIFS - AVXL, SEEL among premarket gainers https://seekingalpha.com/news/3439476-avxl-seel-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3439476-avxl-seel-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439475\" data-ts=\"1551709443\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EVOK\" target=\"_blank\">EVOK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439475-evoke-pharma-receives-preliminary-fda-communication-on-gimoti-nda-shares-down-51-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evoke Pharma receives preliminary FDA communication on Gimoti NDA; shares down 51% premarket</a></h4><ul> <li>Evoke Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a>) has <a href=\"https://seekingalpha.com/pr/17431653-evoke-pharma-receives-preliminary-fda-communication-gimoti-nda\" target=\"_blank\">received</a> a multi-disciplinary review &#40;DR&#41; letter from the FDA in association with the Gimoti 505(b)(2) NDA.</li><li>A DR letter is used to convey preliminary thoughts on deficiencies identified during the initial stage of NDA review.</li>   <li>The letter described concerns in three sections: Chemistry; Clinical and Clinical Pharmacology not within the parameters for bioequivalence for abbreviated NDAs.</li>  <li>The Company plans to respond to the deficiencies raised in the DR letter to allow time for potential FDA review prior to the PDUFA date, April 1.</li>  <li>Shares are down <font color=\"red\">51%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439475\" data-linked=\"Evoke Pharma receives preliminary FDA communication on Gimoti NDA; shares down 51% premarket\" data-tweet=\"$EVOK - Evoke Pharma receives preliminary FDA communication on Gimoti NDA; shares down 51% premarket https://seekingalpha.com/news/3439475-evoke-pharma-receives-preliminary-fda-communication-on-gimoti-nda-shares-down-51-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3439475-evoke-pharma-receives-preliminary-fda-communication-on-gimoti-nda-shares-down-51-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439472\" data-ts=\"1551709247\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PM\" target=\"_blank\">PM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439472-philip-morris-trims-profit-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Philip Morris trims profit guidance</a></h4><ul> <li>Philip Morris International (NYSE:<a href='https://seekingalpha.com/symbol/PM' title='Philip Morris International Inc.'>PM</a>) trims <a href=\"https://seekingalpha.com/pr/17431762-philip-morris-international-inc-revises-full-year-2019-reported-diluted-earnings-per-share\" target=\"_blank\">full-year guidance</a> to adjust for class action lawsuits in Quebec, although the ultimate liability is still unclear.</li> <li>The company now sees FY19 EPS of at least $5.28 vs. $5.37 at least prior and $5.41 consensus.</li> <li>Shares of Philip Morris are <font color=\"red\">down 0.64%</font> premarket to $86.95.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439472\" data-linked=\"Philip Morris trims profit guidance\" data-tweet=\"$PM - Philip Morris trims profit guidance https://seekingalpha.com/news/3439472-philip-morris-trims-profit-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3439472-philip-morris-trims-profit-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439471\" data-ts=\"1551709202\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XBIO\" target=\"_blank\">XBIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439471-xenetic-bio-up-11-premarket-on-acquisition-of-car-t-platform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xenetic Bio up 11% premarket on acquisition of CAR T platform</a></h4><ul><li>Thinly traded nano cap Xenetic Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/XBIO' title='Xenetic Biosciences, Inc.'>XBIO</a>) is up <font color=\"green\">11% </font>premarket on light volume in reaction to its <a href=\"https://seekingalpha.com/pr/17431549-xenetic-biosciences-inc-nasdaq-xbio-announces-agreement-acquire-innovative-car-t-technology\" target=\"_blank\">acquisition </a>of a CAR T platform technology called XCART, developed at The Scripps Research Institute (together with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry) which can potentially improve the safety and effectiveness of cell therapy for B-cell lymphomas via generating patient- and tumor-specific CAR T cells.</li><li>Under the terms of the deal, the company will acquire all the outstanding shares of Hesperix S.A., a newly formed Swiss entity that owns all non-Scripps XCART rights, for an undisclosed sum. It will exclusively license Scripps' rights in exchange for 7.5M XBIO common shares.</li><li>The transaction should close next quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439471\" data-linked=\"Xenetic Bio up 11% premarket on acquisition of CAR T platform\" data-tweet=\"$XBIO - Xenetic Bio up 11% premarket on acquisition of CAR T platform https://seekingalpha.com/news/3439471-xenetic-bio-up-11-premarket-on-acquisition-of-car-t-platform?source=tweet\" data-url=\"https://seekingalpha.com/news/3439471-xenetic-bio-up-11-premarket-on-acquisition-of-car-t-platform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439463\" data-ts=\"1551708523\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439463-evok-and-se-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EVOK and SE among premarket losers</a></h4><ul><li>Evoke Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/EVOK' title='Evoke Pharma, Inc.'>EVOK</a>) <font color=\"red\">-52%</font> on <a href=\"https://seekingalpha.com/pr/17431653-evoke-pharma-receives-preliminary-fda-communication-gimoti-nda\" target=\"_blank\">receiving</a> preliminary FDA communication on Gimoti NDA.</li><li>The Children's Place (NASDAQ:<a href='https://seekingalpha.com/symbol/PLCE' title='The Children&#39;s Place Retail Stores, Inc.'>PLCE</a>) <font color=\"red\">-12%</font> on <a href=\"https://seekingalpha.com/news/3439390-childrens-place-retail-stores-misses-1_00-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li>Bio-Path Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a>) <font color=\"red\">-13%</font>.</li><li>Sea (NYSE:<a href='https://seekingalpha.com/symbol/SE' title='Sea Ltd'>SE</a>) <font color=\"red\">-8%</font>.</li><li>NantHealth (NASDAQ:<a href='https://seekingalpha.com/symbol/NH' title='NantHealth'>NH</a>) <font color=\"red\">-6%</font>.</li><li>Tonix Pharmaceuticals Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>) <font color=\"red\">-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439463\" data-linked=\"EVOK and SE among premarket losers\" data-tweet=\"$EVOK $PLCE $BPTH - EVOK and SE among premarket losers https://seekingalpha.com/news/3439463-evok-and-se-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3439463-evok-and-se-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439453\" data-ts=\"1551708262\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVTA\" target=\"_blank\">NVTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439453-chardan-sees-43-upside-in-invitae-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chardan sees 43% upside in Invitae in premarket analyst action</a></h4><ul><li>Invitae (NYSE:<a href='https://seekingalpha.com/symbol/NVTA' title='Invitae'>NVTA</a>) initiated with Buy rating and $29 (43% upside) price target at Chardan Capital Markets. Shares up <font color=\"green\">2% </font>premarket.</li><li>MannKind (NASDAQ:<a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a>) initiated with Outperform rating and $3 (69% upside) price target at SVB Leerink. Shares up <font color=\"green\">3% </font>premarket.</li><li>Zoetis (NYSE:<a href='https://seekingalpha.com/symbol/ZTS' title='Zoetis'>ZTS</a>) upgraded to Buy with a $110 (15% upside) price target at Stifel. Shares up <font color=\"green\">1%</font> premarket.</li><li>ImmunoGen (NASDAQ:<a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a>) downgraded to Neutral with a $3.50 (39% upside) (from $18) price target at H.C. Wainwright after failed late-stage study of mirvetuximab soravtansine. Shares up <font color=\"green\">2% </font>premarket. Downgraded to Market Perform with a $3 price target at SVB Leerink.</li><li>Universal Health Services (NYSE:<a href='https://seekingalpha.com/symbol/UHS' title='Universal Health Services Inc.'>UHS</a>) downgraded to Neutral with a $147 (4%) price target at JPMorgan.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439453\" data-linked=\"Chardan sees 43% upside in Invitae in premarket analyst action\" data-tweet=\"$NVTA $IMGN $ZTS - Chardan sees 43% upside in Invitae in premarket analyst action https://seekingalpha.com/news/3439453-chardan-sees-43-upside-in-invitae-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3439453-chardan-sees-43-upside-in-invitae-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439455\" data-ts=\"1551707951\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KNDI\" target=\"_blank\">KNDI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439455-kandi-technologiesplus-7-after-new-jv-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kandi Technologies +7% after new JV deal</a></h4><ul> <li>Kandi Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a>) says its joint venture with Geely signed a strategic cooperative agreement for operating government-accredited vehicles with China Resources Vehicle and Ship Natural Gas Co.</li><li>The company says it's thrilled to have the opportunity to collaborate with such a respectable enterprise in China Resources Zhejiang.</li>     <li>KNDI  <font color=\"green\">+7.10%</font> premarket to  $8.30.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17431679-kandi-jv-company-signs-strategic-cooperative-agreement-china-resources-zhejiang-vehicle-ship\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3439455\" data-linked=\"Kandi Technologies +7% after new JV deal\" data-tweet=\"$KNDI - Kandi Technologies +7% after new JV deal https://seekingalpha.com/news/3439455-kandi-technologiesplus-7-after-new-jv-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3439455-kandi-technologiesplus-7-after-new-jv-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439452\" data-ts=\"1551707653\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZS\" target=\"_blank\">ZS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439452-fbn-raises-zscaler-to-street-high-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FBN raises Zscaler to Street-high target</a></h4><ul><li>FBN Securities raises Zscaler's (NASDAQ:<a href='https://seekingalpha.com/symbol/ZS' title='Zscaler'>ZS</a>) PT from $50 to $70, a new Street-high target citing the \"very strong\" <a href=\"https://seekingalpha.com/news/3438731-zscaler-beats-0_10-beats-revenue\" target=\"_blank\">Q2 results</a> and outlook.</li><li>The firm cites Zscaler's revenue acceleration even in the face of tougher Y/Y comparisons and the \"even faster\" billings growth with the overall results suggesting a 20% ASP increase.</li><li>Rating reiterated at Outperform.</li><li>Zscaler shares are<font color=\"green\"> up 0.6%</font> pre-market to $60.95.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439452\" data-linked=\"FBN raises Zscaler to Street-high target\" data-tweet=\"$ZS - FBN raises Zscaler to Street-high target https://seekingalpha.com/news/3439452-fbn-raises-zscaler-to-street-high-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3439452-fbn-raises-zscaler-to-street-high-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439451\" data-ts=\"1551707439\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRON\" target=\"_blank\">CRON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439451-cronos-sells-whistler-stake-to-aurora-cannabis-for-c-24_6m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cronos sells Whistler stake to Aurora Cannabis for C$24.6M</a></h4><ul><li>Cronos Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a>) (<font color=\"green\">+2%</font> premarket) has <a href=\"https://seekingalpha.com/pr/17431237-cronos-group-inc-exits-investment-whistler-medical-marijuana-corporation\" target=\"_blank\">sold </a>its 19% stake in Whistler Medical Marijuana Corp. to Aurora Cannabis (NYSE:<a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a>) (<font color=\"green\">+1%</font> premarket) for C$24.6M in ACB common stock.</li><li>Specifically, CRON received ~2.5M ACB common shares valued at $9.77 per share and is eligible to receive an additional C$7.6M of shares based on the achievement of certain milestones.</li><li>About a year ago, CRON owned a <a href=\"https://www.newcannabisventures.com/cronos-group-ups-investment-in-whistler-medical-marijuana/\" target=\"_blank\">21.5% stake</a> in Whistler, one of the first licensed cannabis producers in Canada, based on an investment of ~C$175M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439451\" data-linked=\"Cronos sells Whistler stake to Aurora Cannabis for C$24.6M\" data-tweet=\"$CRON $ACB - Cronos sells Whistler stake to Aurora Cannabis for C$24.6M https://seekingalpha.com/news/3439451-cronos-sells-whistler-stake-to-aurora-cannabis-for-c-24_6m?source=tweet\" data-url=\"https://seekingalpha.com/news/3439451-cronos-sells-whistler-stake-to-aurora-cannabis-for-c-24_6m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>82&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439446\" data-ts=\"1551706584\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DVA\" target=\"_blank\">DVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439446-dialysis-providers-down-premarket-on-potential-new-u-s-payment-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dialysis providers down premarket on potential new U.S. payment plan</a></h4><ul><li>DaVita (NYSE:<a href='https://seekingalpha.com/symbol/DVA' title='DaVita HealthCare Partners Inc.'>DVA</a>) (<font color=\"red\">-4%</font>) and Fresenius Medical Care (NYSE:<a href='https://seekingalpha.com/symbol/FMS' title='Fresenius Medical Care AG & Co. KGAA'>FMS</a>) (<font color=\"red\">-3%</font>) are both in the red premarket in apparent response to the news that the Trump administration is working on a <a href=\"https://www.reuters.com/article/us-usa-healthcare-dialysis/u-s-seeks-to-cut-dialysis-costs-with-more-home-care-versus-clinics-idUSKCN1QL0G6\" target=\"_blank\">new payment approach</a> for treating kidney disease patients that favors home care and transplants, a potential change that could significantly impact clinic-based dialysis services providers.</li><li>The U.S. government is looking to cut the $114B it spends each year to treat chronic kidney disease and end-stage renal disease. The U.S. Centers for Medicare and Medicaid Services &#40;CMS&#41; is considering a trial payment design aimed at improved care in the early stages of kidney disease, better access to transplants and an emphasis on home dialysis.</li><li>The initiative, if fully implemented, could be bullish for CVS Health (NYSE:<a href='https://seekingalpha.com/symbol/CVS' title='CVS Health Corporation'>CVS</a>), which plans to offer home dialysis, and startups <a href=\"https://www.crickethealth.com/\" target=\"_blank\">Cricket Health</a> and <a href=\"http://www.somatus.com/\" target=\"_blank\">Somatus</a>.</li><li>Fresenius' recent takeover of NxStage Medical appears prescient considering its focus on home dialysis.</li><li>Related ticker: American Renal Associates (NYSE:<a href='https://seekingalpha.com/symbol/ARA' title='American Renal Associates Holdings'>ARA</a>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439446\" data-linked=\"Dialysis providers down premarket on potential new U.S. payment plan\" data-tweet=\"$DVA $FMS $CVS - Dialysis providers down premarket on potential new U.S. payment plan https://seekingalpha.com/news/3439446-dialysis-providers-down-premarket-on-potential-new-u-s-payment-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3439446-dialysis-providers-down-premarket-on-potential-new-u-s-payment-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>73&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439441\" data-ts=\"1551706313\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LNG\" target=\"_blank\">LNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439441-cheniere-energyplus-3_6-on-report-china-may-buy-18b-of-nat-gas\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cheniere Energy +3.6% on report China may buy $18B of nat gas</a></h4><ul><li>Cheniere Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/LNG' title='Cheniere Energy, Inc'>LNG</a>)<font color=\"green\"> jumps 3.6%</font> in premarket trading after the <em>Wall Street Journal </em>reports that China and the U.S. are close to coming to a trade agreement under which China <a href=\"https://www.wsj.com/articles/u-s-china-close-in-on-trade-deal-11551641540?mod=hp_lead_pos1\" target=\"_blank\">would buy $18B of natural gas</a> from Cheniere.</li><li>Bloomberg cites people familiar with the matter.</li><li>China is offering to increase purchases of U.S. goods, to lower tariffs on U.S. farm, chemical, auto, and other products, and to accelerate removing foreign-ownership limitations on car ventures.</li><li>Hurdles still remain, such as whether enforcement provisions are considered strong enough, th<em>e WSJ </em>reports.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439441\" data-linked=\"Cheniere Energy +3.6% on report China may buy $18B of nat gas\" data-tweet=\"$LNG - Cheniere Energy +3.6% on report China may buy $18B of nat gas https://seekingalpha.com/news/3439441-cheniere-energyplus-3_6-on-report-china-may-buy-18b-of-nat-gas?source=tweet\" data-url=\"https://seekingalpha.com/news/3439441-cheniere-energyplus-3_6-on-report-china-may-buy-18b-of-nat-gas\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439438\" data-ts=\"1551705928\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBBY\" target=\"_blank\">BBBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439438-bed-bath-beyondminus-3-after-barclays-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bed, Bath &amp; Beyond -3% after Barclays downgrade</a></h4><ul> <li>Bed, Bath &amp; Beyond (NASDAQ:<a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a>) drifts lower after a Monday morning downgrade from Barclays to an Underweight rating from Equal Weight.</li> <li>The investment firm isn't seeing signs of a turnaround by BBBY. \"It will be highly difficult for the company to build a home furnishing/decor business, which appears to be a critical factor in the ultimate success of a turnaround,\" warns analyst Matthew McClintock.</li> <li>Shares of Bed Bath &amp; Beyond are <font color=\"red\">down 2.94%</font> in premarket trading to $16.20 vs. a 52-week trading range of $10.46 to $23.28.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439438\" data-linked=\"Bed, Bath &amp; Beyond -3% after Barclays downgrade\" data-tweet=\"$BBBY - Bed, Bath &amp; Beyond -3% after Barclays downgrade https://seekingalpha.com/news/3439438-bed-bath-beyondminus-3-after-barclays-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3439438-bed-bath-beyondminus-3-after-barclays-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439437\" data-ts=\"1551705685\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439437-qualcomm-launches-new-apple-patent-challenge\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qualcomm launches new Apple patent challenge</a></h4><ul><li>Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) <a href=\"https://www.reuters.com/article/us-apple-qualcomm/qualcomm-launches-patent-challenge-to-apple-ahead-of-antitrust-case-idUSKCN1QL143?feedType=RSS&amp;feedName=topNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FtopNews+%28News+%2F+US+%2F+Top+News%29\" target=\"_blank\">alleges</a> in a San Diego federal court that Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) violated three of its patents and asks for tens of millions of dollars in damages.</li><li>Qualcomm has filed a series of patent actions against Apple around the world that will conclude before the antitrust trial starting in April, which will hear Apple's challenge to QCOM's business model.</li><li>U.S. District Judge Dana Sabraw will open an eight-day trial today deciding whether Apple violated Qualcomm's patents with its iPhones that contain Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) chips.</li><li>Qualcomm shares are <font color=\"green\">up 0.8%</font> pre-market to $54.65.</li><li>Apple shares are <font color=\"green\">up 0.5%</font> to $175.88.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439437\" data-linked=\"Qualcomm launches new Apple patent challenge\" data-tweet=\"$QCOM $AAPL $INTC - Qualcomm launches new Apple patent challenge https://seekingalpha.com/news/3439437-qualcomm-launches-new-apple-patent-challenge?source=tweet\" data-url=\"https://seekingalpha.com/news/3439437-qualcomm-launches-new-apple-patent-challenge\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>135&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439435\" data-ts=\"1551705374\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RKDA\" target=\"_blank\">RKDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439435-arcadia-up-26-premarket-on-hemp-license-in-hawaii\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arcadia up 26% premarket on hemp license in Hawaii</a></h4><ul><li>Nano cap Arcadia Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/RKDA' title='Arcadia Biosciences'>RKDA</a>) is up <font color=\"green\">26%</font> premarket on modestly higher volume in reaction to its Industrial Hemp Pilot Program License in Hawaii, allowing it to <a href=\"https://seekingalpha.com/pr/17431014-arcadia-biosciences-receives-first-industrial-hemp-program-license-hawaii\" target=\"_blank\">cultivate </a>industrial hemp there for agricultural and academic research.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439435\" data-linked=\"Arcadia up 26% premarket on hemp license in Hawaii\" data-tweet=\"$RKDA - Arcadia up 26% premarket on hemp license in Hawaii https://seekingalpha.com/news/3439435-arcadia-up-26-premarket-on-hemp-license-in-hawaii?source=tweet\" data-url=\"https://seekingalpha.com/news/3439435-arcadia-up-26-premarket-on-hemp-license-in-hawaii\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439434\" data-ts=\"1551705217\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDS\" target=\"_blank\">DDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439434-jpmorgan-warns-on-dillards\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan warns on Dillard&#39;s</a></h4><ul> <li>JPMorgan lowers Dillard's (NYSE:<a href='https://seekingalpha.com/symbol/DDS' title='Dillard&#39;s Inc.'>DDS</a>) to an Underweight rating after having the department store stock lined up at Neutral.</li><li>The JP analyst team warns about the impact of a high level of inventory that has built up at Dillard's.</li> <li>The firm drops its price target on Dillard's to $57 from $68 to rep 10% downside potential.</li> <li>Shares of Dillard's are <font color=\"red\">down 1.44%</font> in premarket trading to $74.14. The 52-week low for Dillard's is $55.73.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3439434\" data-linked=\"JPMorgan warns on Dillard&#39;s\" data-tweet=\"$DDS - JPMorgan warns on Dillard&#39;s https://seekingalpha.com/news/3439434-jpmorgan-warns-on-dillards?source=tweet\" data-url=\"https://seekingalpha.com/news/3439434-jpmorgan-warns-on-dillards\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439432\" data-ts=\"1551705076\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PEI\" target=\"_blank\">PEI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439432-pennsylvania-reit-doesnt-see-jcpenney-store-closings-sharesplus-2_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pennsylvania REIT doesn&#39;t see JCPenney store closings; shares +2.5%</a></h4><ul><li>Pennsylvania REIT (NYSE:<a href='https://seekingalpha.com/symbol/PEI' title='Pennsylvania Real Estate Investment Trust'>PEI</a>) <font color=\"green\">gains 2.5%</font> in premarket trading after confirming that it doesn't expect any JC Penney closures at its properties as a result of the <a href=\"https://seekingalpha.com/pr/17427928-jcpenney-reports-fourth-quarter-fiscal-2018-earnings\" target=\"_blank\">retailer's announcement</a> of 2019 store closings.</li><li>\"With no unleased department stores in our core portfolio and among the lowest exposure to Sears in the sector, we are uniquely positioned to execute on our strategy and capitalize on the opportunity to further diversify our earnings through the addition of multifamily and hotel units across our portfolio,\" says CEO Joseph F. Coradino.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3439396-washington-prime-reports-progress-filling-toys-r-us-spaces\" target=\"_blank\">Washington Prime reports progress on filling Toys R Us spaces</a> (March 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3439432\" data-linked=\"Pennsylvania REIT doesn&#39;t see JCPenney store closings; shares +2.5%\" data-tweet=\"$PEI - Pennsylvania REIT doesn&#39;t see JCPenney store closings; shares +2.5% https://seekingalpha.com/news/3439432-pennsylvania-reit-doesnt-see-jcpenney-store-closings-sharesplus-2_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3439432-pennsylvania-reit-doesnt-see-jcpenney-store-closings-sharesplus-2_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439429\" data-ts=\"1551704984\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439429-clovis-rubraca-tablets-for-women-now-available-in-germany-shares-are-up-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clovis&#39; rubraca tablets for women now available in Germany; shares are up 5% premarket</a></h4><ul> <li>Clovis Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a>) <a href=\"https://seekingalpha.com/pr/17431006-clovis-oncology-announces-availability-rubraca-rucaparib-tablets-women-relapsed-ovarian\" target=\"_blank\">announces</a> that Rubraca (rucaparib) is now available by prescription in Germany as monotherapy       for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal       cancer who are in response (complete or partial) to platinum-based       chemotherapy.</li>      <li>Rucaparib is the first PARP inhibitor licensed for       an ovarian cancer treatment indication in the EU and is now the first to       be available for both treatment and maintenance treatment among eligible       patients.</li>               <li>Clovis Oncology intends to launch Rubraca in other European countries to follow in 2019 and 2020.</li><li>Shares are up <font color=\"green\">5%</font> premarket.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3439429\" data-linked=\"Clovis&#39; rubraca tablets for women now available in Germany; shares are up 5% premarket\" data-tweet=\"$CLVS - Clovis&#39; rubraca tablets for women now available in Germany; shares are up 5% premarket https://seekingalpha.com/news/3439429-clovis-rubraca-tablets-for-women-now-available-in-germany-shares-are-up-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3439429-clovis-rubraca-tablets-for-women-now-available-in-germany-shares-are-up-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439425\" data-ts=\"1551704707\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STAY\" target=\"_blank\">STAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439425-extended-stay-up-2_5-on-goldman-touch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Extended Stay up 2.5% on Goldman touch</a></h4><ul><li>Significant upside and limited downside risk merits an upgrade to Buy for Extended Stay America (NYSE:<a href='https://seekingalpha.com/symbol/STAY' title='Extended Stay America, Inc.'>STAY</a>) from Goldman's Stephen Grambling.</li><li>Management's focus on strategic alternatives, the building of company-owned pipeline of hotels ahead of schedule, and idiosyncratic drivers of growth driving a re-acceleration in REVPAR are all key factors, says Grambling.</li><li>STAY could fetch $26 in a sale based on both comps and a sum-of-the-parts analysis, says Grambling - that's <font color=\"green\">40% upside</font>.</li><li>Shares are <font color=\"green\">higher by 2.5%</font> premarket to $19.07.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439425\" data-linked=\"Extended Stay up 2.5% on Goldman touch\" data-tweet=\"$STAY - Extended Stay up 2.5% on Goldman touch https://seekingalpha.com/news/3439425-extended-stay-up-2_5-on-goldman-touch?source=tweet\" data-url=\"https://seekingalpha.com/news/3439425-extended-stay-up-2_5-on-goldman-touch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439422\" data-ts=\"1551704556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASND\" target=\"_blank\">ASND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439422-ascendis-pharma-up-56-premarket-on-positive-transcon-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ascendis Pharma up 56% premarket on positive TransCon data</a></h4><ul><li>Thinly traded Ascendis Pharma A/S (NASDAQ:<a href='https://seekingalpha.com/symbol/ASND' title='Ascendis Pharma'>ASND</a>) is up <font color=\"green\">56% </font>premarket on increased volume in response to <a href=\"https://seekingalpha.com/pr/17431116-ascendis-pharma-announces-weekly-transcon-growth-hormone-demonstrated-superiority-primary\" target=\"_blank\">positive results</a> from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02781727?lead=ascendis&amp;phase=2&amp;rank=3\" target=\"_blank\">heiGHt</a>, evaluating once-weekly TransCon Growth Hormone in children with pediatric growth hormone deficiency &#40;GHD&#41;.</li><li>The study met the primary endpoint demonstrating superiority to daily TransCon in terms of annualized height velocity &#40;AHV&#41; at week 52. Specifically, the treatment difference was 0.86 cm/year, a statistically significant result (p=0.0088). Also, the separation was statistically valid from week 26 onward.</li><li>The safety profile was on par with the daily regimen.</li><li>Weekly dosing is a major advantage since GHD patients need therapy over a period of years.</li><li>The data will be presented at ENDO 2019 on March 24.</li><li>Topline data from a second Phase 3, fliGHt, should be available next quarter. The company expects to file a U.S. marketing application in H1 2020.</li><li>Management will host a conference call this morning at 8:00 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439422\" data-linked=\"Ascendis Pharma up 56% premarket on positive TransCon data\" data-tweet=\"$ASND - Ascendis Pharma up 56% premarket on positive TransCon data https://seekingalpha.com/news/3439422-ascendis-pharma-up-56-premarket-on-positive-transcon-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3439422-ascendis-pharma-up-56-premarket-on-positive-transcon-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439419\" data-ts=\"1551704388\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439419-evercore-raises-amazon-on-gross-profit-potential\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Evercore raises Amazon on gross profit potential</a></h4><ul><li>Evercore raises its Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) price target from $1,800 to $1,965 saying that gross profit has become a \"more important indicator\" than Y/Y revenue growth.</li><li>Key quote: \"As such, we remain bullish on AMZN at least in part because the company\u2019s gross profit is expected to grow ~400bps faster than revenue for AMZN over the next 3 years.\"</li><li>Amazon shares are <font color=\"green\">up 0.9%</font> pre-market to $1,686.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439419\" data-linked=\"Evercore raises Amazon on gross profit potential\" data-tweet=\"$AMZN - Evercore raises Amazon on gross profit potential https://seekingalpha.com/news/3439419-evercore-raises-amazon-on-gross-profit-potential?source=tweet\" data-url=\"https://seekingalpha.com/news/3439419-evercore-raises-amazon-on-gross-profit-potential\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439417\" data-ts=\"1551704092\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEM\" target=\"_blank\">NEM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439417-newmont-rejects-barrick-bid-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Newmont rejects Barrick bid (updated)</a></h4><ul><li>A headline across Bloomberg says Newmont Mining (NYSE:<a href='https://seekingalpha.com/symbol/NEM' title='Newmont Mining Corporation &#40;Holding Company&#41;'>NEM</a>) will reject Barrick Gold's (NYSE:<a href='https://seekingalpha.com/symbol/GOLD' title='Barrick Gold Corporation'>GOLD</a>) hostile bid as soon as today.</li><li>NEM <font color=\"red\">-1.8%</font> premarket; GOLD <font color=\"red\">-0.9%</font></li><li><strong>Updated at 8:10 AM ET:</strong> <a href=\"https://seekingalpha.com/pr/17431359-newmont-board-unanimously-determines-barrick-s-unsolicited-negative-premium-proposal-newmont\" target=\"_blank\">Newmont says its merger</a> with Goldcorp (NYSE:<a href='https://seekingalpha.com/symbol/GG' title='Goldcorp Inc.'>GG</a>) should provide better shareholder value than a sale to Barrick Gold.</li><li>A <a href=\"https://event.on24.com/wcc/r/1952473/C5AC3067BE6C7740A2D324BE629DA649\" target=\"_blank\">conference call</a> is set for 9 ET.</li><li><a href=\"https://www.newmont.com/investor-relations/investor-events/default.aspx\" target=\"_blank\">Presentation slides here</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3439417\" data-linked=\"Newmont rejects Barrick bid (updated)\" data-tweet=\"$NEM $GOLD $GG - Newmont rejects Barrick bid (updated) https://seekingalpha.com/news/3439417-newmont-rejects-barrick-bid-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3439417-newmont-rejects-barrick-bid-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439414\" data-ts=\"1551703534\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ODP\" target=\"_blank\">ODP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439414-office-depotplus-11-after-inking-alibaba-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Office Depot +11% after inking Alibaba deal</a></h4><ul> <li>Office Depot (NYSE:<a href='https://seekingalpha.com/symbol/ODP' title='Office Depot Inc.'>ODP</a>) announces a new strategic collaboration with Alibaba (NYSE:<a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a>).</li><li>The collaboration is expected to leverage the companies\u2019 respective strengths to       serve U.S. SMBs, including Office Depot\u2019s deep relationships with more       than 10M U.S. business customers.</li><li>The company says the goal of the collaboration is       to empower U.S. small- and medium-sized businesses to grow by       tapping into the global B2B e-commerce marketplace.</li><li>ODP  <font color=\"green\">+10.96%</font> premarket to  $3.95.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17431123-office-depot-alibaba-com-form-strategic-collaboration-serve-u-s-businesses\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3439414\" data-linked=\"Office Depot +11% after inking Alibaba deal\" data-tweet=\"$ODP $BABA - Office Depot +11% after inking Alibaba deal https://seekingalpha.com/news/3439414-office-depotplus-11-after-inking-alibaba-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3439414-office-depotplus-11-after-inking-alibaba-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3439413\" data-ts=\"1551703509\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRK\" target=\"_blank\">MRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3439413-european-advisory-group-backs-new-dosing-regimen-for-mercks-keytruda\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group backs new dosing regimen for Merck&#39;s Keytruda</a></h4><ul><li>The European Medicines Agency's advisory committee CHMP has adopted a <a href=\"https://seekingalpha.com/pr/17431130-european-medicines-agency-adopts-positive-opinion-merck-s-keytruda-pembrolizumab-six-week\" target=\"_blank\">positive opinion</a> recommending approval for a dosing regimen of 400 mg via 30-minute infusion every six weeks for all indications for Merck's (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>) KEYTRUDA (pembrolizumab) when used alone.</li><li>The PD-1 inhibitor is currently administered via a 30-minute infusion of 200 mg every three weeks for monotherapy use.</li><li>A final decision from the European Commission usually takes ~60 days.</li><li>Shares are up <font color=\"green\">1%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3439413\" data-linked=\"European advisory group backs new dosing regimen for Merck&#39;s Keytruda\" data-tweet=\"$MRK - European advisory group backs new dosing regimen for Merck&#39;s Keytruda https://seekingalpha.com/news/3439413-european-advisory-group-backs-new-dosing-regimen-for-mercks-keytruda?source=tweet\" data-url=\"https://seekingalpha.com/news/3439413-european-advisory-group-backs-new-dosing-regimen-for-mercks-keytruda\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}